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Men ought to know that from nothing else but the brain come joys, delights, laughter 
and sports, and sorrows, griefs, despondency, and lamentations. ... And by the same 
organ we become mad and delirious, and fears and terrors assail us, some by night, 
and some by day, and dreams and untimely wanderings, and cares that are not 
suitable, and ignorance of present circumstances, desuetude, and unskillfulness. All 
these things we endure from the brain, when it is not healthy... 
 
Hippocrates, On the Sacred Disease (400 BCE) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To my parents and my grandparents,  
who never doubted me, 
with all my love. 
 
Abstract 
i 
 
Abstract 
Anxiety disorders, such as posttraumatic stress disorder (PTSD), are characterized 
by a high prevalence and debilitating symptoms. However, the current first-line 
treatment for these conditions, which consists of selective serotonin reuptake 
inhibitors (SSRIs) and cognitive behavioral therapy, alongside symptomatic treatment 
with benzodiazepines, does not represent by far a functional solution for all affected 
patients. Therefore, identifying and characterizing novel candidates for alternative 
anxiolytic therapies are a crucial focus of psychiatric and neurobiological research. 
This study focuses on Neuropeptide S (NPS), a newly identified endogenous 
neuropeptide that has been shown to exert strong anxiolytic effects upon 
intracerebral injection in rodents. In an approach that combines basic research with 
incipient clinically relevant application, novel mechanisms and brain targets of NPS-
mediated anxiolytic effects were identified, and a noninvasive application procedure 
also applicable in patients, namely the intranasal administration, was established for 
the first time for NPS in mouse models. 
In a first step, the feasibility of intranasal NPS delivery was established in mice using 
fluorophore-coupled NPS to allow intracerebral tracking. This method permitted for 
the first time tracking of intranasally applied substances within the brain at a single-
cell resolution. These results not only proved the applicability of intranasal NPS 
administration in the mouse, but also allowed identification and characterization of 
hitherto undescribed cerebral NPS target cells, which were shown to be most likely 
exclusively neurons. Moreover, specific uptake of fluorescently labeled NPS in the 
hippocampus provided the first direct evidence linking this brain region, a well-known 
major player in the regulation of fear expression, to the NPS circuitry. Further 
investigation into the functional role of the hippocampus in NPS-elicited anxiolytic 
effects revealed that local microinjections of NPS into the ventral CA1 (vCA1) region 
are sufficient to elicit anxiolysis in C57BL6/N mice on the elevated plus maze (EPM). 
In a second step, behavioral and molecular effects of intranasal NPS treatment were 
characterized in C57BL/6N mice. Intranasal application of NPS was shown here to 
produce anxiolytic effects similar to those described by others after intracerebral 
injection. This finding represents the basis for the implementation of a future NPS-
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based therapy via nasal sprays in patients suffering from anxiety disorders. 
Furthermore, the molecular effects of NPS treatment on cerebral protein expression 
were examined here for the first time. This research led to identification of novel 
downstream targets of NPS-mediated regulation in the hippocampus and the 
prefrontal cortex. These new targets include proteins involved in the glutamatergic 
system and in synaptic plasticity, both of which are known to be dysregulated in 
anxiety disorders. 
Finally, the effects of intranasal NPS treatment, hitherto described only in non-
pathological animal models, were examined for the first time in mouse models of 
anxiety disorders, namely the high anxiety behavior (HAB) mice and a mouse model 
of PTSD. In HAB mice, NPS treatment elicited anxiolytic effects similar to those 
observed in C57BL/6N mice. In the mouse model of PTSD, NPS counteracted 
disease-related changes in expression levels of hippocampal synaptic proteins. 
To sum up, this work expands the current state-of-knowledge concerning the 
molecular and mechanistic background of NPS-mediated anxiolysis by characterizing 
the role of the hippocampus in the NPS circuitry and by identifying novel downstream 
targets of NPS. The data on anxiolytic effects of intranasal NPS treatment especially 
in mouse models of anxiety disorders furthermore establishes the therapeutic 
potential of NPS as a novel anxiolytic treatment. 
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1. Introduction 
1.1. The endocrine stress response 
The term “stress”, used for a long time only in physical sciences as a synonym for 
“tension”, was coined in its physiological sense by Hans Selye as late as the 1930s. 
Nowadays, it is applied almost exclusively to designate the biological phenomenon 
that Selye defined as “the non-specific response of the body to any demand placed 
upon it” (Selye, 1956).  
The most important characteristic of stress is the disruption of systemic homeostasis 
(Cannon, 1932). The human organism can respond to stressors on different levels. In 
most cases, this response is beneficial (Chrousos and Gold, 1992), since it allows 
adaptation to extraordinary circumstances via two well-described different endocrine 
pathways, known as the central stress pathways (Praag et al., 2004; Steckler et al., 
2005): 1) activation of the sympathetic nervous system, a fast process leading to 
immediate response readiness; and 2) activation of the hypothalamo-pituitary-adrenal 
(HPA) axis, a slower reaction resulting in long-term readjustment of internal 
processes.  
The sympathetic nervous system is activated to achieve a fight-or-flight response to 
an imminent threat. This leads to increased release of catecholamines, especially 
adrenaline (from the adrenal medulla) and noradrenaline (released peripherally from 
the adrenal medulla and centrally from the locus coeruleus (LC)). Adrenaline 
increases cardiac frequency and blood pressure, dilates the bronchi, and activates 
lipolysis and glucose release and biosynthesis. Noradrenaline, on the other hand, 
also possesses a neurotransmitter function, by which it can increase arousal and 
modulate cognitive and affective processes (Steckler et al., 2005).  
Long-term adaptation to stressors is additionally mediated via increased activity of 
the HPA axis (see Figure 1). The HPA axis involves complex interactions between 
various brain structures and glands. Stressors act as stimuli which lead to increased 
secretion of the neuropeptides vasopressin and corticotropin-releasing hormone 
(CRH) from the paraventricular nucleus (PV) of the hypothalamus. These in turn are 
transported from the median eminence to the pituitary and stimulate, in the anterior 
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lobe of the pituitary, release of adrenocorticotropic hormone (ACTH), which ultimately 
activates the adrenal cortex to upregulate synthesis of glucocorticoid hormones such 
as cortisol (or corticosterone in rats and mice). These glucocorticoids then exert, 
mainly via the glucocorticoid receptor (GR) and the mineralocorticoid receptor (MR), 
a variety of actions, such as suppression of immune activity and increased glucose 
availability to adapt to stressful environmental cues. Interestingly, effects of 
glucocorticoids on synaptic plasticity have also been postulated as potential players 
in stress-induced changes in synaptic plasticity via regulation of the glutamatergic 
system (Krugers et al., 2010). This process occurs at least partly by corticosterone-
mediated increase 1) in the release of glutamate (Karst et al., 2005); 2) in the 
availability of subunits 1 and 2 (GluR1 and GluR2) of the α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) receptor (a ionotropic glutamate receptor) 
at the postsynaptic site (Groc et al., 2008); and 3) in the synaptic insertion of GluR2-
containing AMPA receptors (Karst et al., 2005; Martin et al., 2009). 
 
Figure 1. Schematic overview of the HPA axis response to stress. 
A mechanism for avoiding pathological changes due to stress is the strict regulation 
of the HPA axis by negative feedback such as GR-mediated decrease in 
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hypothalamic CRH production (Holsboer, 1999), which allows restoration of 
homeostasis in hormone and neurotransmitter levels. Thus, there are no adverse 
consequences for the organism (Chrousos and Gold, 1992). Chronic stress, 
however, can lead to impairment of this negative feedback loop: hypothalamic CRH 
expression can no longer be suppressed by glucocorticoids (Praag et al., 2004). This 
is the case in many patients suffering from affective disorders like depression and 
anxiety disorders. 
1.2. The HPA axis in psychiatric disorders 
Major signs of a dysregulated HPA axis include changes in circulating levels of CRH, 
vasopressin, ACTH and cortisol, which are due inter alia to differential regulation of 
their transcription and translation rates. Thus, in major depression, the HPA system 
was found to be hyperactive, with increased CRH production (Raadsheer et al., 
1995) and increased levels of circulating ACTH (Deuschle et al., 1997); on the other 
hand, CRH deficiency has also been observed in a minority of patients (Posener et 
al., 2000). Panic disorder (PD) and generalized anxiety disorder (GAD) have been 
associated with increased concentrations of cortisol in the cerebrospinal fluid (CSF) 
and hypertrophy of the pituitary and adrenal glands due to hyperactivity (Chalmers et 
al., 1996). 
The long-lasting changes in CRH and cortisol levels found in affective disorders have 
also been postulated to trigger behavioral effects, including increased anxiety. 
Anxiety is defined as pathological and generalized fear and manifests itself as a 
persistent, unpleasing and often unsubstantiated feeling of worriedness, in the 
absence of any acute stimulus that might trigger fear (American Psychiatric 
Association, 2000). It is comorbid with many psychiatric conditions, such as 
depression (Pini et al., 1997). In animal models, high doses of CRH have been 
shown to elicit anxiogenic effects, such as decrease in exploration of novel 
environments and increased freezing and acoustic startle response (ASR) (Heinrichs 
et al., 1997); similarly, transgenic mice that overproduce CRH are hyperanxious 
(Stenzel-Poore et al., 1994).  
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1.3. Anxiety disorders 
Anxiety in itself can also constitute an independent pathological condition, as in the 
case of anxiety disorders. According to the fourth edition of the Diagnostic and 
Statistical Manual of Mental Disorders (DSM-IV), these include panic disorder (PD), 
generalized anxiety disorder (GAD), phobias (social, specific and agoraphobia), 
acute stress disorder and posttraumatic stress disorder (PTSD) (American 
Psychiatric Association, 2000). The lifetime prevalence of any anxiety disorder is 28.8 
% (Kessler et al., 2005) and the symptoms are debilitating. Thus, in PD, patients are 
prone to recurrent panic attacks which involve acute fear and discomfort occurring in 
the absence of true danger and coupled to activation of the sympathetic nervous 
system (American Psychiatric Association, 2000).   
Anxiety and fear regulation involve activation of and interaction between various 
brain structures. Most important among them are the amygdala, the prefrontal cortex 
and the hippocampus. A combination of patient and animal studies have pinpointed 
the amygdala as the primary region involved in the response to fearful stimuli 
(Mathew et al., 2008; Shin and Liberzon, 2009); together with the hippocampus, it 
has been related to learning of fear conditioning (Kjelstrup et al., 2002; Maren and 
Holt, 2004; McHugh et al., 2004). The prefrontal cortex on the other hand seems to 
play a large role in fear extinction, which also requires formation of new memories 
(Santini et al., 2004; Kim et al., 2010). These structures have been shown to be 
involved in the pathology of anxiety disorders. In PD, amygdala hyperactivity has 
been reported in subgroups of PD patients (Domschke et al., 2008), and in the 
medial prefrontal cortex, gray matter volumes were found to be reduced (Asami et al., 
2008; Uchida et al., 2008).  
Dysregulations of endocrine and neurotransmitter systems in anxiety disorders 
include among others: 1) dysregulation of the HPA axis, leading to altered levels in 
CRH, ACTH and cortisol (see also 1.2.); 2) increased activity of the glutamatergic 
system; 3) reduction in levels of monoamine transmitters such as noradrenaline and 
serotonin; and 4) changes in levels of neuropeptides, such as Substance P and 
Neuropeptide Y (NPY) (Mathew et al., 2008).   
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Currently, treatment of anxiety disorders consists in a combination of psychotherapy, 
where the gold standard is cognitive-behavioral therapy (Mathew et al., 2008), and 
pharmacotherapy. The first-line pharmacological treatment are selective serotonin 
reuptake inhibitors (SSRIs), alongside symptomatic treatment with benzodiazepines 
(Ravindran and Stein, 2010b). The SSRIs work mainly by inhibiting the reuptake of 
serotonin from the presynaptic cleft via the presynaptic serotonin transporter, thus 
increasing overall cerebral levels of serotonin. Benzodiazepines target a specific 
binding site of the ionotropic γ-amino butyric acid subtype A (GABAA) receptor and 
enhance the effect of the inhibitory neurotransmitter GABA, reducing amygdala 
activation and thereby achieving anxiolysis. However, these medications do not 
represent a functional solution for all anxiety disorders. For instance, in PTSD 
patients, while SSRI treatment generally has good results in the case of civilian 
trauma, it failed to be effective in most studies with combat-related PTSD (Shiromani 
et al., 2009). 
1.3.1. Posttraumatic stress disorder (PTSD) 
Posttraumatic stress disorder (PTSD) is one of the most common anxiety disorders 
(Steckler et al., 2005) and affects a minority of persons exposed to a trauma such as 
rape, assault or combat, as well as natural disasters and accidents (Yehuda and 
LeDoux, 2007). Approximately 6.8 % of people exposed to a traumatic event develop 
PTSD, whereas around 75 % of the total population are exposed to trauma once in 
their life (Kessler et al., 1995, 2005). Given the wide range of causes that may lead to 
PTSD, the risk of developing this disorder applies to the entire population.  
DSM-IV defines the core symptoms of PTSD as: 1) persistent reexperiencing of the 
traumatic event; 2) persistent avoidance of trauma-related stimuli and numbing of 
general responsiveness following trauma; and 3) hyperarousal following trauma 
(American Psychiatric Association, 2000). For fulfillment of these diagnostic criteria, 
this symptom complex has to persist for at least 1 month. PTSD symptoms can occur 
starting several weeks up to decades after the event.  
Since PTSD is not a mandatory consequence of experiencing a trauma, research has 
also been focusing on identifying pre-traumatic factors that may influence the 
development of this disease. These factors include structural brain abnormalities 
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(Yehuda and LeDoux, 2007) and environmental, genetic, and epigenetic 
contributions (Afifi et al., 2010; Schmidt et al., 2011; Yehuda et al., 2011). Thus, 
hippocampal volume was found to be reduced in PTSD patients (Rauch et al., 2006; 
Bremner, 2007), but additionally, smaller hippocampal volumes have also been 
correlated to higher risk of developing PTSD (Gilbertson et al., 2002; Pitman et al., 
2006). These results indicate a role of the hippocampus in PTSD vulnerability 
(Pitman et al., 2001). Twin studies have shown significantly greater risk for 
developing PTSD in monozygotic twins independent of differences in environment 
(True et al., 1993). However, gene-environment interactions generally play a major 
role in creating a predisposition for developing PTSD (Afifi et al., 2010). Thus, the 
effect of gene variants and environment has been examined in PTSD especially for 
genes associated with regulation of the HPA axis and coding inter alia for CRH 
(Tyrka et al., 2009), GR (Bachmann et al., 2005) and FK506 binding protein 5 
(FKBP5) (Binder et al., 2008). In the gene coding for FKBP5, which regulates 
cortisol-binding affinity to GR and nuclear translocation of GR, four single nucleotide 
poylmorphisms (SNPs) were found to interact with the severity of child abuse as 
predictor of adult PTSD symptoms. Changes in gene expression may also occur via 
epigenetic modifications, which are in themselves a consequence of environmental 
influences, especially in early life-phases (Schmidt et al., 2011). A strong hint in this 
direction is provided by analysis of gene expression patterns in survivors of the 
terrorist attacks on the World Trade Center, which revealed different gene expression 
of e.g. FKPB5 in patients with current PTSD (Yehuda et al., 2009). 
The ongoing search for alternative PTSD medication is of great importance, since the 
current therapy situation is not satisfactory. Despite a wide variety of available 
therapeutics ranging from SSRIs to symptomatic treatment with benzodiazepines 
(Ravindran and Stein, 2009, 2010b; Steckler and Risbrough, 2011), specific targeting 
of PTSD core symptoms is as yet still not possible. Although treatment of anxiety 
disorders with either antidepressants or a combination of antidepressants and 
cognitive therapy is usually effective, it requires weeks for onset of action and 
furthermore often leads only to partial remission (Furukawa et al., 2006; Ravindran 
and Stein, 2009; Rodrigues et al., 2011). Benzodiazepines on the other hand act very 
fast, however, due to their high abuse potential as well as other negative side-effects 
including sedation and dependency, they are not optimal as a long-term anti-anxiety 
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therapy (Cloos and Ferreira, 2009; Ravindran and Stein, 2009; Tan et al., 2010). It is 
therefore essential to develop effective anxiolytics with a rapid onset of action and 
lacking the undesirable side-effects of benzodiazepines (Ravindran and Stein, 
2010a; Rudolph and Knoflach, 2011; Steckler and Risbrough, 2011). In order to 
achieve this goal, it is crucial to work towards a better understanding of PTSD 
pathology and thereby identify new potential drug targets. 
The neurobiological underpinnings of PTSD are as yet imperfectly understood, as is 
the case with most psychiatric disorders. Some players have however already been 
identified, such as the serotonin system and the HPA axis. The serotonin system, 
target of SSRI therapeutic actions, is also a major player in PTSD pathology (Praag 
et al., 2004). Activation of the serotonergic receptor system leads to rapid anxiolytic 
effects; in PTSD, however, decreased levels of serotonin coupled to impaired 
receptor activation and redistribution of receptor expression may contribute to 
symptoms like hyperarousal and intrusive memories (Southwick et al., 1999b). The 
HPA axis is the most extensively characterized system with regard to PTSD (Ehlert et 
al., 2001; Shea et al., 2005; de Kloet et al., 2006). For instance, some studies have 
shown overall hypocortisolism in PTSD patients (Yehuda et al., 1995), accompanied 
by changes in the noradrenergic system, which may be partly responsible for the 
state of hyperarousal and facilitated retrieval of traumatic memories (flashbacks) 
experienced in PTSD (Southwick et al., 1999a). 
Apart from the HPA axis and the serotonin system, PTSD also goes along with 
disturbance of the balance in various other neurotransmitter systems. Dysregulation 
has been found in the glutamatergic system (Heim and Nemeroff, 2009; Rossi et al., 
2009), as well as in synaptic plasticity (Alfarez et al., 2006; Kozlovsky et al., 2007; 
Ježek et al., 2010; Acheson et al., 2011). Other neurotransmitters that have been 
associated with PTSD include neuropeptides. For example, NPY was found to be 
decreased in the plasma and CSF of combat veterans with PTSD (Rasmusson et al., 
2000; Sah et al., 2009); galanin mRNA expression was reduced in the hippocampus 
and frontal cortex in a mouse model of PTSD (Kozlovsky et al., 2009); and 
endogenous opioids have been associated with some symptoms of PTSD (Heim and 
Nemeroff, 2009).  
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Novel approaches for PTSD treatment aim at restoring homeostasis in these 
neurotransmitter circuits. Examples include modulating the activity of the 
glutamatergic system for instance via N-methyl-D-aspartate (NMDA) receptor 
antagonists (Steckler and Risbrough, 2011) and D-cycloserine (DCS), an NMDA 
receptor agonist, which enhances extinction and/or replacement of traumatic 
memories (Yamamoto et al., 2008). Neuropeptides have also emerged as promising 
candidates for alternative anxiolytic therapies (Hökfelt et al., 2003). For instance, the 
aforementioned NPY was associated with resistance to and recovery from PTSD 
both in humans (Yehuda et al., 2006) and in animal models of PTSD (Cohen et al., 
2011). Consequently, a variety of ligands and activity modulators for the various NPY 
receptor subtypes have been designed (Brothers and Wahlestedt, 2010). However, 
the wide variety of NPY receptor subtypes makes specific modulation of the 
NPYergic system with a view towards reducing anxiety a challenge that has not as 
yet been overcome. Ideally, therapeutic substances would target only one type of 
receptor very specifically in the central nervous system (CNS).  
1.4. Neuropeptide S and its receptor, NPSR 
In contrast to NPY, animal experiments showed that Neuropeptide S (NPS) exerts its 
effects via one receptor only (Zhu et al., 2010). This neuropeptide was identified by 
reverse pharmacology as the ligand for a previously orphan G-protein coupled 
receptor (GPCR), GPR154, that henceforth became known as the NPS receptor 
(NPSR) (Xu et al., 2004). NPS is a 20 amino acid long neuropeptide, with a highly 
conserved sequence among various species of vertebrates (Figure 2A), which hints 
at its crucial importance in the brain circuitry (Xu et al., 2004; Reinscheid, 2007). The 
name of the peptide is derived from the aminoterminal residue in its sequence, 
serine, which is conserved across all species. Structure-activity studies on NPS 
showed its aminoterminal structures (NPS 1-10), which are also the best conserved 
across species, to be especially relevant for its biological activity and for activation of 
the cognate receptor; the C-terminal structures may however be required for in vivo 
activity (Roth et al., 2006). 
NPSR, the only known NPS receptor, is coupled to either Gs or Gq (Reinscheid et al., 
2005). Upon binding to its receptor, NPS leads to intracellular increase in cyclic 
adenosine monophosphate (cAMP) and Ca2+ levels, and to activation of the mitogen-
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activated protein kinase (MAPK) cascade (Reinscheid et al., 2005) (Figure 2B). 
These effects hint at a potential role of NPS in the regulation of cell proliferation. 
NPS can interact with and modulate various neurotransmitter systems (Raiteri et al., 
2009; Boeck et al., 2010; Mochizuki et al., 2010; Si et al., 2010), most important 
among which is the glutamatergic system (Han et al., 2009; Okamura et al., 2010). 
Furthermore, NPS treatment has regulatory effects on the HPA axis (Figure 2C), 
increasing plasma ACTH and corticosterone concentrations in vivo in rats after 
intracerebral injection, and stimulating CRH and vasopressin after incubation with 
hypothalamic explants (Smith et al., 2006). Most importantly, NPS effects do not 
seem to be mediated via the benzodiazepine binding site of the GABAA receptor 
(Leonard et al., 2008), which suggests that NPS treatment will not have the common 
side effects of benzodiazepine treatment (Cloos and Ferreira, 2009; Tan et al., 2010; 
Ravindran and Stein, 2010b). 
 
Figure 2.  NPS, NPSR and NPS-elicited effects. A Sequence of active NPS in various 
species (Xu et al., 2004). B Effects of NPS upon binding to NPSR on the 
intracellular level as described in (Reinscheid et al., 2005). C Effects of NPS on 
a systemic level upon intracerebroventricular (ICV) injection in rodents: 
behavioral effects as described in (Xu et al., 2004; Leonard et al., 2008) and 
effects on the HPA axis as described in (Smith et al., 2006). 
Despite the variety of its effects, NPS expression in the rat is restricted almost 
exclusively to three brain regions: the peri-locus coeruleus, the parabrachial nucleus 
and the principal sensory 5 nucleus of the trigeminus (Xu et al., 2004, 2007). Also, in 
the mouse, NPS precursor mRNA is found in only two brain regions: the Kölliker-
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Fuse nucleus and the pericoerulear area (Clark et al., 2011). NPSR, on the other 
hand, is widely expressed throughout the brain in regions ranging from cortical areas 
such as the olfactory, somatosensory and motor cortex to deep subcortical structures 
such as the amygdaloid and thalamic nuclei (Xu et al., 2007). There are however 
discrepancies between reports on NPSR mRNA and protein expression patterns in 
the rat brain, as well as between murine and rat NPSR mRNA expression. In the rat, 
in situ hybridization (ISH) studies reveal no NPSR mRNA expression in the CA1, CA2 
and CA3 regions and in the dentate gyrus (Xu et al., 2007). In contrast, protein 
expression studies performed using an NPSR antibody describe presence of NPSR 
protein in those same areas, albeit at low expression levels (Leonard and Ring, 
2011). Similarly, NPSR mRNA was found to be expressed in the murine basolateral 
amygdala (BLA), where also strong effects on neuronal activity were elicited after 
local treatment with this substance (Jüngling et al., 2008; Clark et al., 2011), whereas 
in the rat BLA, NPSR mRNA expression was very low and protein expression was 
completely absent. Due to these conflicting reports, the ultimate identity of the NPS 
target neurons and target brain regions that contribute to its behavioral effects still 
remains elusive. 
Intracerebroventricular (ICV) injection into mice revealed that NPS elicits a variety of 
behavioral effects, including increased locomotion and hyperarousal (Xu et al., 2004; 
Rizzi et al., 2008). Most relevant for the thesis at hand however are the well-
described strong anxiolytic effects of NPS treatment (Figure 2C), which highlight the 
potential of NPS as a novel alternative therapy for anxiety disorders, including PTSD 
(Xu et al., 2004; Jüngling et al., 2008; Leonard et al., 2008; Rizzi et al., 2008; Fendt 
et al., 2010). Also, a transcriptionally and functionally hyperactive NPSR variant 
expressing an A/T SNP in the coding region has been associated with panic disorder 
(Okamura et al., 2007; Domschke et al., 2010) and overinterpretation of fear-related 
experiences (Raczka et al., 2010; Dannlowski et al., 2011; Lennertz et al., 2011). 
Moreover, NPS-producing neurons have also been reported to become activated 
upon stress exposure (Liu et al., 2011). All these findings support the hypothesis that 
endogenous NPS plays an important role in the anxiety circuit and has strong 
potential as an alternative therapy of anxiety-related symptoms.  
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1.5. Intranasal application 
In order to further investigate the therapeutic potential of NPS with a view towards 
implementing it as a therapy in patients suffering from pathological anxiety, one of the 
first steps consists in establishing a noninvasive administration method that can be 
easily applied in humans. One such possible alternative to the intracerebral injection 
commonly used in animal models is the intranasal application.  
Intranasal application has been shown both in humans and in animals to be 
appropriate for targeting the CNS in the case of several substances, including 
neuropeptides (e.g. oxytocin and vasopressin) (Gozes et al., 2000; Born et al., 2002; 
Dufes et al., 2003; Guastella et al., 2010; Shi et al., 2010). Use of radioactively 
labeled ligands (Figure 3) has led to identification of two different pathways which 
substances can follow in order to reach the brain after intranasal application (Thorne 
et al., 1995, 2004). Along one pathway, substances are transported along the 
olfactory nerve via the olfactory bulb to rostral and subcortical brain regions. The 
second pathway follows the myelin sheaths of the trigeminal nerves to target caudal 
cerebral structures such as the brainstem and the cerebellum. Timeline studies have 
shown this process to be surprisingly rapid, with substances reaching the brain within 
minutes of administration and remaining detectable up to hours after treatment 
(Thorne et al., 2004; Dhuria et al., 2009).  
 
Figure 3.  Targeting of CNS via intranasal application (adapted from (Thorne et al., 2004)). A 
Cerebral substance distribution after intranasal application follows two different 
pathways: the peripheral olfactory system to the olfactory bulb and rostral brain 
(red) and the peripheral trigeminal system to the brainstem (blue). B 
Autoradiography of representative sagittal brain section after intranasal 
application of radioactively labeled ligand. 
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Given the previous success of intranasal therapy with some neuropeptides (Born et 
al., 2002; Guastella et al., 2010), NPS seems to be a prime candidate for intranasal 
application. However, since the nose-brain barrier permeability of substances is 
highly influenced by their polarity and molecular weight (Ozsoy et al., 2009; Dhuria et 
al., 2010), it is very difficult to predict whether a given compound will successfully 
reach the brain upon intranasal instillation. Consequently, the feasibility of this 
procedure has to be established afresh for every substance of interest. In addition, 
due to the largely unknown pharmacodynamics and pharmacokinetics which differ 
substantially between intranasally administered and intracerebrally injected agents 
(Thorne et al., 1995; Thorne and Frey, 2001), new protocols have to be established 
for characterizing the treatment-induced phenotype. 
1.6. Mouse models of anxiety disorders 
To test the potential of intranasally applied NPS as a therapeutic, it is necessary to 
examine its effects in animal models of the pathological conditions that should 
subsequently be treated in patients. While it is not possible to check for paranoia in 
mouse models of schizophrenia or for flashbacks in mouse models of PTSD, it is 
possible, using various behavioral paradigms, to describe changes in the anxiety- 
and fear-related behavior inherent to the animals. It has also been proven in many 
cases that this type of behavior can be influenced by anxiolytic and anti-depressive 
medication (Garcia et al., 2008) similarly to patients (Autry et al., 2011), which 
supports the validity of these models. Most importantly, these models allow for 
differentiating between trait and state anxiety. Trait anxiety is defined as an individual 
predisposition to respond, whereas state anxiety is a context-dependent response to 
certain stimuli and is accompanied by physiological arousal as described above (see 
1.1.) (Endler and Kocovski, 2001). Trait and state anxiety can both be pathologically 
altered. 
In this work, two different mouse models exhibiting increased anxiety-like behavior 
were used to test the anxiolytic effects of intranasally applied NPS: 1) high anxiety 
behavior (HAB) mice, which model the condition of trait anxiety; and 2) a mouse 
model of PTSD, which represents the condition of state anxiety. 
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1.6.1. The HAB mice, a mouse model for inbred anxiety 
HAB mice are a mouse model of pathologically high anxiety, inbred for over 40 
generations in a CD1 background (Krömer et al., 2005; Landgraf et al., 2007; Bunck 
et al., 2009; Hambsch et al., 2010). HAB mice are selected at 7-13 weeks for their 
specific high anxiety behavior on the elevated plus-maze (EPM) in comparison to low 
behavior anxiety (LAB) mice, which are similarly inbred; outbred CD1 mice are 
employed as normal anxiety behavior (NAB) controls (Krömer et al., 2005). The EPM, 
an elevated platform with two open and two enclosed arms (see Figure 4A) allows for 
precise quantification of anxiety-like behavior by comparing the time mice spend in 
the closed arms to the time they spend in the open arms (Lister, 1987) (see Figure 
4B). Mice tend to explore new environments; however, they also instinctively prefer to 
remain in the closed arms where they feel more protected than in the open. In 
exceptionally anxious mice, the amount of time spent exploring is significantly biased 
in favor of the closed arms. In mice characterized by lower-than-typical anxiety, the 
bias is reversed. The behavior on the EPM at the age of testing is considered to 
predict later anxiety and stress-coping behavior (Krömer et al., 2005). 
  
Figure 4.  Overview of the EPM. A Setup. B Schematic overview of mouse behavior on the 
EPM: hyper-anxious mice will tend to restrict themselves to the closed arms, while 
mice showing low anxiety will preferentially explore the open arms. 
The comparability of this model to the situation in patients has been established on 
the molecular level as well. For instance, it was found that HAB and LAB mice show 
significant differences in expression of various proteins associated with stress 
responsiveness, as well as metabolic differences (Landgraf et al., 2007; Filiou et al., 
2011; Zhang et al., 2011; Filiou and Turck, 2012). Thus, in HAB mice, expression and 
release of vasopressin, a neuropeptide with a major role in the HPA axis (see 1.1.), 
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are strongly upregulated due to a SNP in the vasopressin promoter region, whereas 
the opposite situation is observed in LAB mice (Landgraf et al., 2007). This model is 
especially interesting since it allows for investigation of high trait anxiety on a very 
complex level of interactions between neuroendocrine, behavioral and genetic factors 
(Landgraf et al., 2007). Therefore, it complements very well the mouse model of 
PTSD, which represents a model of state anxiety. 
1.6.2. The mouse model of PTSD 
The mouse model used here has been established in the C57BL/6N strain and is 
based on an electrical footshock as one-time trauma exposure (Siegmund and 
Wotjak, 2007). The difference to classical Pavlovian conditioning, which also uses a 
footshock as conditioning stimulus, consists in that, in the case described here, the 
electrical current applied is more than twice as high (1.5 mA as opposed to 0.7 mA), 
and ca. five times higher than the pain threshold of C57BL/6N mice (Siegmund et al., 
2005), making this experience considerably more painful and therefore traumatic. 
Differences in behavior were considered relevant 28 days after shock, an incubation 
period which allows for attenuation of acute and PTSD-non-related effects and also 
takes into consideration the possibility of delayed phenotype onset. 28 days after 
trauma, shocked mice have been shown to develop a PTSD-like phenotype 
(Siegmund and Wotjak, 2007). This is characterized by: 1) increased sensitized fear 
as measured by their freezing behavior in a neutral context, corresponding to the 
physiological response in patients upon exposure to trauma-related stimuli that may 
symbolize or resemble an aspect of the traumatic event (trigger phenomenon); 2) 
reduced social response accompanied by social withdrawal in a social interaction 
test, corresponding to significant impairment in the social behavior of patients; and 3) 
hyperarousal as shown by heightened startle reaction in response to neutral tones of 
increasing intensities, exactly as observed in PTSD patients (Siegmund and Wotjak, 
2007; Golub et al., 2011). Additionally, cerebral changes that have been described in 
PTSD patients are also found in shocked mice, such as hippocampal shrinkage 
(Wignall et al., 2004; Golub et al., 2011).  
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1.7. Goals 
Anxiety disorders are among the most common psychiatric conditions, with a high 
prevalence and severe impact not only on the life quality of the individual, but also on 
the well-being of society as a whole. The current treatment situation is unsatisfactory, 
and in consequence, developing alternative medication and better characterizing its 
mode of action is of crucial importance. 
The present work is situated at the crossroad between basic and applied research. 
Therefore, the main purpose consisted in characterizing the mechanisms of action 
and the targets of NPS, a novel and promising candidate for the development of 
alternative anxiolytic therapeutics, as well as in validating a therapeutic procedure 
that can easily be applied in humans. 
The first goal was establishing the feasibility of intranasal NPS treatment in mice. 
Here, two important points had to be proved: (1) that intranasally applied NPS can 
bypass the nose-brain barrier to reach the brain, especially the regions known to be 
involved in the anxiety circuit like amygdala and hippocampus; and (2) that intranasal 
application of NPS elicits similar anxiolytic effects as intracerebral injection.  
The second focal point of investigation concerned the regulatory effects of NPS 
treatment on cerebral protein expression. This was especially relevant in the case of 
systems that have already been associated with NPS effects and that were shown to 
be dysregulated in PTSD, such as the glutamatergic system and proteins involved in 
synaptic plasticity.  
Finally, the therapeutic potential of NPS was examined in mouse models of two 
different pathological conditions, i.e. the HAB mice and the mouse model of PTSD. 
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2. Methods and materials 
For a complete list of all devices, materials, substances, kits, buffer recipes and 
software used in this work please see Supplementary Tables 1-6. 
2.1. Cell biology 
2.1.1. Generation of tagged NPSR constructs 
In order to investigate the trafficking of NPSR and its interactions with its ligand in 
vitro, it was necessary, given the lack of a functioning NPSR antibody, to generate 
tagged NPSR constructs. This process was performed in multiple steps: 1) isolation 
of total mRNA from murine brain regions known to express NPSR mRNA; 2) reverse 
transcription of total mRNA into cDNA; 3) amplification of NPSR cDNA with specific 
NPSR primers; and 4) cloning of NPSR cDNA into plasmids to produce recombinant 
NPSR tagged with either enhanced green fluorescent protein (EGFP) or FLAG.  
2.1.1.1. Isolation of total mRNA from murine brain regions 
Total mRNA was isolated from a section of the murine brain which contained regions 
where NPSR mRNA had been previously described, such as the hippocampus, the 
paraventricular hypothalamic nucleus, cortical regions and amygdaloid nuclei (Figure 
5). The isolated brain part was estimated generously to include as many regions with 
NPSR expression as possible, in order to maximize NPSR mRNA yield. 
Total mRNA was isolated according to the TRIzol protocol established in our 
laboratory. The brain tissue sample was taken up in 2 ml RNase-free plastic tubes, 1 
ml TRIzol was added and the sample was homogenized with a turrax at room 
temperature (RT). The homogenized sample was shaken vigorously by hand and 
incubated for 5 min at RT. For phase separation, 200 µl choloroform were added, the 
sample was shaken vigorously by hand for 15 seconds and then incubated for 2-3 
min at RT. Subsequently, the sample was centrifuged at 13000 rotations per minute 
(rpm) for 15 min at 4 °C, and the watery colorless phase was transferred into a new 
tube. For precipitation, 0.5 ml isopropanol were added and the solution was mixed by 
inverting the tube 10 times. After 10 min incubation at RT, the sample was 
centrifuged at 13 krpm and 4 °C for 10 min and the supernatant was discarded. This 
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was followed by a washing step on ice. 1 ml 70 % ethanol was added and the pellet 
washed by inverting and flicking the tubes. After centrifugation at 13 krpm and 4 °C 
for 10 min, the supernatant was discarded and the pellet was dried at RT for ca. 60 
min (until all visible traces of ethanol had disappeared). The pellet was then 
redissolved in 50 µl H2O treated with diethylpyrocarbonate (DEPC) (DEPC-H2O) and 
stored at -80 °C. Total mRNA concentration was determined by measurement with a 
Nanophotometer. 
 
Figure 5. Isolated murine brain regions for isolation of total mRNA. A Overview of murine 
brain. Solid black lines indicate cutting points for brain region isolation. B Sagittal 
brain section where dotted black lines indicate selected lateral overview plates 
(adapted from (Franklin and Paxinos, 2007)). 1 DEn: dorsal endopiriform cortex; 
BLA: basolateral amygdala, anterior part; BLP: basolateral amygdala, posterior 
part; CA1-3 regions of the hippocampus. 2 Cg1,2: cingulate cortex; PV: 
paraventricular hypothalamic nucleus; MnPO: median preoptic nucleus; 3V: third 
ventricle. 3 S1: somatosensory cortex; ACo: cortical amygdala; CeC: central 
amygdala, cortical part; CeM: central amygdala, medial part; BMA, BMP: 
basomedial amygdala, anterior and posterior part; AHi: amygdalohippocampal 
region.  
2.1.1.2. Reverse transcription of total mRNA into cDNA 
Reverse transcription was performed using the Omniscript Reverse Transcription Kit 
according to the manufacturer’s instructions. In brief, 0.1 µg/µl total mRNA were 
added to a master mix containing a final concentration of 1x RT buffer, dNTP mix at 
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0.5 mM each dNTP, 1 µM Oligo-dT primers, 0.5 unit/µl RNase inhibitor, 0.2 units/µl 
Omniscript Reverse Transcriptase and RNase-free water to the desired volume. The 
solution was incubated for 1 hour at 37 °C in a PCR thermocycler to allow for reverse 
transcription and the resulting cDNA was stored at -20 °C thereafter. 
2.1.1.3. Amplification of NPSR cDNA from total cDNA 
The NPSR cDNA sequence for amplification was selected to include only the 
translatable sequence based on the complete NPSR cDNA sequence shown below 
(NCBI Reference Sequence: NM_175678). The sequence of interest is highlighted in 
yellow and contains a start and a stop codon. 
       61 gagacagtga gacctgaccc tgcctgagcc atgccagcca acctcacaga gggcagcttt 
      121 catgccaacc agactgtgcc gatgctagat tcttccccag tagcttgcac tgaaattgtg 
      181 acgttcactg aagcactggt ggctgaggag tggggctcct tctactcctc ctttaagaca 
      241 gaacagctga taaccctgtg ggtcctgttt gtcgtcacta ttgtgggaaa ctctgttgtg 
      301 ctgttctcca cgtgcagaag aaaaagaaag tccagaatga ccttctttgt gacacaattg 
      361 gccatcacag actccttcac gggcctgatc aacatcttga cagacattat ttggcgattc 
      421 acaggagact tcatggcccc tgacctggtt tgcagagtcg tccgctactt gcaggttgtc 
      481 ctgctgtatg cctctaccta cgtcctggtg tccctcagca tagacagata ccatgccatc 
      541 gtttacccca tgaagtttct tcaaggagag aagcaagcca aagtcctcat cggaatagcg 
      601 tggagcctct cgttcctgtt ctccattccc acgctgatca tatttgggaa aaggacactt 
      661 tccaatggtg aggtgcagtg ctgggcactg tggccggatg actcctactg gaccccgtac 
      721 atgaccatcg tcgcctttct ggtgtacttc attcccttgg caattatcag cgttatctat 
      781 ggccttgtga tccgaactat ttggatgaaa agcaaaaccc atgagacggt gatttccaac 
      841 tgctcagatg gcaaactatg ctgcagctac aaccgagggc tcatctctaa ggcaaaaatc 
      901 aaggccatca agtatagcat cgtcataatc cttgctttca tctgctgctg gagcccatac 
      961 ttcctctttg acatattaga caacttcaac gtccttccag acaccaagga gcgtttctat 
     1021 gcctctgtga ttatccagaa cctgcccgcc ttgaacagtg ccattaaccc cctcatctac 
     1081 tgcatcttca gcagctccat ctgctccccc tgcaagatgc aaagatcaca ggattccaga 
     1141 atgacatacc gagagagaag cgagagacac gagatgcaga ttctctccaa gccggaattc 
     1201 atctaaaccc tgaggcagta gtgctaggct gaacttagtc agctctcctg gatctttacc 
  
NPSR was amplified from total cDNA using specific primers for cloning into pEGFP-
C1 and pcDNA3.1 (-) plasmids (see Table 1). For tagging NPSR with FLAG, the 
FLAG-tag sequence (shown here in blue) was inserted into the reverse primer and 
the stop codon of the NPSR cDNA sequence was replaced by a stop codon within 
the reverse primer. The primers contained inserted restriction sites. The primer 
sequences are listed in Table 2 (restriction sites shown in red). 
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Table 1. Plasmids used for cloning EGFP-NPSR and NPSR-FLAG constructs. 
Plasmid Manufacturer 
pEGFP-C1 Clontech, Mountain View, CA, USA 
pcDNA3.1 (-) Invitrogen, Darmstadt, Germany 
 
Table 2.   Primer sequences used for amplification of murine NPSR from murine cDNA for 
cloning into pEGFP-C1 and pcDNA3.1 (-). 
Plasmid Primer Primer sequence Restriction enzyme 
Insert 
size 
forward 5’-AATGCCTCGAGTTATGC CAGCCAACCTCACAGAG-3’ XhoI pEGFP-C1 and 
pcDNA3.1 (-) reverse 5’-GCCGCGGATCCTCAGCCT AGCACTACTGCCTC-3’ BamHI 
1150 bp 
forward 5’-CTAGCTCGAGATGCCAGC CAACCTCACAGA-3’  XhoI 
pcDNA3.1 (-) 
with FLAG-tag reverse 
5’-CTAGGGATCCCTACTTG 
TCGTCATCGTCTTTGTAGTC
GATGAATTCCGGCTTGGA 
GA-3’ 
BamHI 
1146 bp 
 
The PCR master mix contained 1 µg template cDNA per reaction volume of 100 µl, 
which included a final concentration of 1x PCR Buffer, dNTPs at 0.2 mM each dNTP, 
1.5 mM MgCl2, forward and reverse primer at 0.5 µM each primer, 2.5 units Taq 
polymerase and autoclaved distilled H2O (dH2O) as needed. 
The PCR program used for amplification was as follows:  
1. initial denaturation: 94 °C – 3 min 
2. denaturation: 94 °C – 45 seconds 
3. annealing: 56 °C – 30 seconds 
4. elongation: 72 °C – 1.5 min 
5. final elongation: 72 °C – 10 min 
6. pause at 4 °C 
 
Products were stored at -20 °C until further use. 
2.1.1.4. Cloning insert into plasmid 
Insertion of the PCR product into the corresponding vector occurred according to the 
“sticky end” principle. Inserts and plasmids were digested with the respective 
enzymes in a 50 µl volume for 2 hours in a water bath at 37 °C. The restriction digest 
40 cycles 
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solution contained 1 µg of plasmid added to 5 µl 10x NEBuffer 3 + 5 µl 10x bovine 
serum albumin (BSA), 4 units restriction enzyme and dH2O.  
Products of the restriction digest were loaded on a 
Tris/Borate/Etylenediaminetetraacetic acid (EDTA) (TBE) agarose gel containing 
0.01 % ethidium bromide (EtBr) and separated by gel electrophoresis. As EtBr 
intercalates in the DNA strands and glows upon UV stimulation, the DNA bands 
could be visualized under UV light and cut from the gel with a scalpel. DNA was 
eluted from the gel with the QIAquick Gel Extraction Kit using a microcentrifuge 
according to the manufacturer’s instructions. In brief, the excised bands were 
weighed in 2 ml tubes and 3 volumes Buffer QG were added to 1 volume of gel (100 
mg ~ 100 µl) and subsequently incubated for 10 min at 50 °C, vortexing every 2-3 
min to speed up agarose solubilization. Afterwards, 1 gel volume isopropanol was 
added to the solution to increase yield and mixed. The mixture was then pipetted into 
a QIAquick spin column and DNA was bound to the column membrane by 
centrifugation at 13.2 krpm for 1 min. The centrifugation was repeated after addition 
of 1 ml Buffer QG to remove all traces of agarose. DNA was washed by addition of 
0.75 ml Buffer PE followed by two centrifugation steps to completely remove all 
ethanol traces. DNA was eluted into a clean 2 ml tube by addition of 30 µl dH2O, 
incubation at RT for 1 min and subsequent centrifugation. Products were stored at -
20 °C. 
To ligate the insert into the vector, insert and vector were added in a 6:1 ratio for 10 
ng vector to 2 µl Reaction Buffer for T4 ligase, 1 µl of T4 ligase and water up to 20 µl 
total volume. The mixture was incubated at room temperature for 10 min and the 
reaction was then stopped by inactivating the enzyme at 65 °C for 15 min (otherwise 
the transformation efficiency would be significantly decreased). Products were stored 
at -20 °C.   
For amplifying the DNA, competent bacteria (E. coli DH5α) were transformed with the 
vectors containing the inserts. Around 10 ng DNA were added to 50 µl solution of 
competent bacteria and incubated on ice for 30 min. The heat-shock was performed 
at 42 °C for 45 seconds, then 900 µl SOC-medium (Super Optimal Broth (SOB) 
medium with 20 mM glucose) were added and followed by incubation for 60 min on a 
thermomixer at 37 °C and 600-700 rpm to initiate ampicillin resistance. The bacterial 
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suspension was plated on lysogeny broth (LB) (containing 1x ampicillin and 
kanamycin) agar plates and incubated overnight at 37 °C. Since the plasmids contain 
an ampicillin resistance gene, only bacteria that have taken up the construct and 
express this gene are expected to grow and form colonies in the presence of 
ampicillin. The next day, colonies were picked with a pipette tip and transferred to an 
Erlenmeyer flask containing 500 ml lysogeny broth (LB) medium with 1x ampicillin 
and then incubated for 14-16 hours at 37 °C on a mixer at 200 rpm to allow for 
bacterial growth. 
DNA was isolated from the bacterial suspension using the PureYield Plasmid 
Midiprep System according to the manufacturer’s instructions. In brief, a lysate was 
prepared by centrifuging cells at 5000 g and resuspending the pellet in Cell 
Resuspension Solution. For DNA purification, the suspension was mixed with Cell 
Lysis Solution (avoiding precipitate formation) and subsequently with Neutralization 
Solution. Cellular debris was cleared by centrifugation at 15000 g for 15 min and by 
vacuum passage through a Clearing Column, which filtered out the lysate and where 
DNA bound to the binding membrane of the Binding Column. Afterwards, the column 
was washed with Column Wash Solution. After drying, DNA was eluted in 600 µl 
Nuclease-Free Water. DNA concentrations were measured with the 
Nanophotometer. Products were stored at -20 °C. Correct insert integration was 
checked by sequencing of the product (outsourced to GATC Biotech AG, Konstanz, 
Germany). 
2.1.2. Transfection of HEK cells with the NPSR constructs 
In order to characterize the behavior of the NPSR constructs on a cellular level, the 
constructs were used to transfect human embryonic kidney (HEK) cells, an 
immortalized cell line that has previously been used to study NPSR distribution 
(Bernier et al., 2006). Cells were cultured in 10 cm dishes in an incubator at 37 °C 
and 5 % CO2, using Dulbecco’s modified Eagle’s medium (DMEM) with 10 % fetal 
calf serum (FCS), 1 % sodium pyruvate and 1 % antibiotic-antimycotic solution. Cells 
were split 1:10 twice a week. For splitting, medium was removed and cells washed 
with phosphate buffered saline (PBS) to remove all traces of FCS which inhibits the 
trypsin used for detaching cells. PBS was removed and trypsin-EDTA solution was 
added. The cells were then incubated for 1 min in the incubator to increase enzyme 
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activity, followed by medium addition, and the cells were taken up in suspension and 
then passaged to another culture vessel.  
For seeding, cells were taken up in suspension, diluted with trypan blue which stains 
dead cells and counted using the Neubauer counting chamber. From the result, the 
number of live cells per ml can be extrapolated according to the following formula:  
number of cells / ml = (number of live cells in all quadrants / 4) x dilution factor x 104 
2.5 x 106 HEK cells per well were seeded in 24-well plates and allowed to grow in the 
incubator until they had reached 50-60 % confluence (ca. 24 hours). The 
transfections were performed using the ExGen 500 in vitro Transfection Reagent. 2 
µg DNA in 100 µl 150 mM NaCl were vortexed gently and spun down briefly, then 6 
equivalents ExGen (3.3 µl) were added, the solution was vortexed for 10 seconds 
and incubated at RT for 10 min to allow formation of DNA/ExGen-complexes. Then 
100 µl solution were pipetted per well and the culture plate was centrifuged for 5 min 
at 280 g at RT. Cells were incubated for 48 hours to allow for expression of construct.  
Correct construct expression was checked on two levels: mRNA and protein level. 
2.1.2.1. Expression of NPSR constructs on mRNA level 
Total mRNA was isolated from transfected cells using the NucleoSpin RNA II Kit 
according to the manufacturer’s instructions. In brief, medium was removed and cells 
washed with PBS, then 350 µl Buffer RA1 containing 1 % β-mercaptoethanol were 
added to lyse the cells. The cells were taken up in suspension and pipetted up and 
down vigorously to improve the lysis process, then the lysate was filtered by passing 
through a NucleoSpin Filter in a centrifugation step of 1 min at 13.2 krpm. The 
supernatant was adjusted for RNA binding by mixing with 350 µl ethanol and the 
RNA was bound to the silica membrane of a NucleoSpin RNA II Column in a 
centrifugation step. The silica membrane was then desalted by addition of 350 µl 
Membrane Desalting Buffer (MDB) and centrifugation for drying. DNA was digested 
by addition of 95 µl DNase reaction mixture (consisting of 10 µl reconstituted DNase 
(rDNase) and 90 µl Reaction Buffer for rDNase) and incubation for 15 min at RT. The 
silica membrane was washed in three steps separated by centrifugation steps of 30 
seconds: 1) 200 µl Buffer RA2 to inactivate the DNase; 2) 600 µl Buffer RA3; and 3) 
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250 µl Buffer RA3. The final centrifugation step lasted 2 min to completely dry the 
membrane. Highly pure, DNA-free RNA was eluted in 40 µl RNase-free H2O.  
Products were stored at -80 °C. 
The total mRNA was reversely transcribed into cDNA as described above (2.1.1.2.) 
and NPSR was amplified specifically via PCR (2.1.1.3.). To check if the isolated 
mRNA amount was similar in both transfected and control samples, actin-beta 
amplification was performed in parallel as described above (2.1.1.3.) with the 
following changes: annealing temperature = 62 °C; and used primers: forward: 5’–
CTACAATGAGCTGCGTGTGGC–3’; reverse: 5’–CAGGTCCAGACGCAGGATGGC–
3’. PCR products were checked for length and intensity by separation via gel 
electrophoresis (2.1.1.4.). 
2.1.2.2. Immunofluorescence of NPSR constructs  
For checking NPSR expression on the protein level, cells were seeded on cover slips 
coated with 0.1 % gelatin. For coating, the cover slips were incubated in a Petri dish 
in the gelatin solution for up to 3 hours at RT. The gelatin was then removed and the 
cover slips were washed three times in PBS and were then stored in PBS at 4 °C in a 
Petri dish sealed with parafilm. 
36 hours after transfection, medium was removed, cover slips were washed three 
times with ice-cold PBS and then fixed in 4 % paraformaldehyde (PFA) solution 
overnight at 4 °C. The next day, cover slips were placed on parafilm, washed three 
times with PBS and then permeabilized by incubation with 0.1 % triton in PBS for 20 
min. All steps were performed at RT; after addition of fluorescent compounds, all 
steps were performed in the dark. After washing, unspecific binding sites were 
blocked by incubation with 10 % BSA in PBS for 60 min in the dark. The blocking 
solution was then removed and the antibody dilution in 1 % BSA in PBS was added 
and incubated for 60 min in the dark. After washing, the secondary fluorophore-
coupled antibody was added followed by an identical incubation step as previously. 
Finally, the cells were washed and counterstained for 10 min with a 1:5000 dilution of 
4’,6-diamidino-2-phenylindole (DAPI) from a stock solution of 1 mg/ml in PBS. DAPI 
intercalates in the DNA and can be stimulated with fluorescent light to emit a blue 
signal, thereby creating a nuclear counterstain. After a last washing step, the cover 
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slips were then mounted with a fluorescence-preserving medium, Shandon Immu-
Mount. 
For the NPSR-FLAG construct, a primary FLAG-antibody was used and detected 
with a secondary antibody coupled to Alexa488 (green). For the EGFP-NPSR 
construct, no staining except the nuclear staining was used, since EGFP already 
emits a green signal that allows for localization of the fusion protein. Primary 
antibodies are listed in Table 3, secondary antibodies are listed in Table 4. 
Table 3. Primary antibodies for immunofluorescence. 
Antibody Dilution Species Manufacturer 
Anti-FLAG 1:100 rabbit Sigma-Aldrich, St Louis, MA, 
USA 
 
Table 4. Secondary antibodies for immunofluorescence. 
Antibody Dilution Species Manufacturer 
Anti-rabbit 
Alexa488 
1:300 donkey Invitrogen, Darmstadt, Germany 
 
Image acquisition was performed using either an epifluorescence or a confocal 
microscope. 
2.1.3. Stimulation with Cy3-NPS 
In order to examine receptor behavior upon ligand stimulation, transfected HEK cells 
were stimulated with a fluorescent NPS conjugate, Cy3-NPS, which emits a red 
signal upon stimulation with light of a certain wavelength. This method allowed for 
tracking of receptor-ligand complex via fluorescent signals.  
To visualize the receptor-ligand complex, a protocol from (Grady et al., 1995) was 
adapted. In brief, 100 nM Cy3-NPS in PBS was added to the cell medium and the 
cells (previously seeded on coated cover slips) were incubated at 4 °C for 60 min to 
allow for binding of the ligand to the membranary receptor and to inhibit cell 
metabolism. Medium was then removed and cells were washed three times with ice-
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cold PBS to remove all traces of unbound ligand. Cells were then either fixed 
immediately in ice-cold PFA as described above (2.1.2.2.), or warm medium was 
added and the cells were incubated in the incubator to allow for receptor-ligand 
internalization and processing, since at 37 °C, the cellular metabolism is again 
upscaled. In cells expressing FLAG-NPSR, immunofluorescent stainings were 
performed (2.1.2.2.); cells expressing EGFP-NPSR were only stained for nuclear 
visualization. 
Image acquisition was performed using either an epifluorescence or a confocal 
microscope. 
2.2. ICV and intranasal application of fluorescent NPS conjugates in mice 
2.2.1. Animals 
For visualization of Cy3-NPS uptake in vivo, 10 weeks old male C56BL/6N mice bred 
in the animal facility of the Max Planck Institute (MPI) of Biochemistry, Martinsried, 
were used. 
2.2.2. Stereotactic surgery and ICV injection 
For stereotactic surgery, the mice were fixed in a stereotactic frame and kept under 
forene (100 %, V/V) anesthesia (active substance: isofluran; induction: 2.5 %; 
maintenance: 1.5 %; in O2; flow rate: 1 l/min) for the entire duration of the surgery 
(ca. 30 min). The mice received acute analgetic treatment with Metacam 
subcutaneously (s.c.) during surgery (0.5 mg/kg; in NaCl). 23 gage stainless-steel 
guide cannulas were implanted unilaterally at the following coordinates: 0.3 mm 
caudal and 1.1 mm lateral from the bregma; and 1.3 mm ventral from the skull 
surface (Figure 6). The guide cannulas were fixed with the aid of two screws and a 
two-component adhesive. The mice were allowed to recover for 7 days after surgery 
to restore system homeostasis. Substance infusions were performed manually on 
mice anesthetized by brief inhalation of isoflurane using a 30 gage injection cannula 
connected to a Tygon tube and a 10 µl Hamilton syringe. After infusion, the injection 
cannula was kept in place for an additional 30 s to prevent substance outflow. Mice 
were injected with 2 µl of either Cy3-NPS or rhodamine-NPS (10 µM) or 
unconjugated rhodamine (1 g/ml) in PBS and sacrificed 30 min after injection. To 
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additionally check the uptake specificity of fluorescent NPS conjugates, 2 µl of native 
rat NPS at 50 or 100 µM in Ringer solution were pre-injected 10 min before injection 
of Cy3-NPS. 
 
Figure 6.  Injection site and distribution pattern of Cy3-NPS. Injection site shown on the left 
as a red star. The hypothesis stated that Cy3-NPS would enter the cerebrospinal 
fluid (CSF) upon ICV delivery and from there distribute throughout the entire brain 
(shown here on the right as red arrows) and be internalized specifically into cells 
expressing active NPSR at the membrane. Brain overview adapted from (Franklin 
and Paxinos, 2007). 
In order to determine whether the internalization of the fluorescent NPS conjugates 
was dependent upon NPSR or upon other mechanisms, these were co-injected with 
specific NPSR antagonists: either [D-Cys(tBu)5]NPS (Camarda et al., 2009) or the 
active enantiomer of 3-oxo-1,1-diphenyl-tetrahydrooxazolo-[3,4-a]pyrazine-7-
carboxylic acid 4-fluoro-benzylamide (SHA 68), (R)-SHA 68, both 1.5 mM (= 150 fold 
concentration of Cy3-NPS) (Okamura et al., 2008; Trapella et al., 2011). Animals 
were sacrificed by cervical dislocation 30 min after injection. 
2.2.3. Intranasal application of fluorescent NPS conjugates 
To determine whether NPS can reach its specific cerebral target cells after intranasal 
delivery, Cy3-NPS was applied intranasally in mice anesthetized with ketamine-
rompun at 0.1 ml/10 g and placed in a supine position, with the head supported at a 
45 degree angle to the body. This has been determined by others to be the optimal 
position in which least substance loss to the sinuses occurs (van den Berg et al., 
2002). Cy3-NPS (10 µM) or unconjugated rhodamine (10 g/ml) in a volume of 7 µl 
were applied alternatingly to each nostril using a 10 µl pipette; after 5 min, the 
procedure was repeated. This break was designed to avoid overfilling of the nostrils 
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and substance loss by exhalation. The mice were sacrificed by cervical dislocation 30 
min after application. 
2.2.4. Brain removal and immunohistochemistry 
After sacrifice, the whole brains were removed immediately and post-fixed in 4 % 
PFA overnight at 4°C, then shock-frozen in methylbutane and stored at -80°C. 
Cryosections of 40 µm were then cut from the olfactory bulb until the first third of the 
cerebellum.  
For observation of the distribution pattern of Cy3-NPS, the sections were thaw-
mounted and counterstained with DAPI for 15 min, then washed by immersion into 
PBS. After mounting with Shandon Immu-Mount, the sections were stored at 4°C. 
To quantify Cy3-NPS uptake between ICV and intranasal administration, a four-point 
scale was used to score both signal intensity and number of labeled cells as follows: 
very strong, +++; strong, ++; moderate, +; weak/scattered, -/+; and no signal, -. 
For characterization of the cells that took up Cy3-NPS on the basis of specific 
markers for various cell types, stainings against these markers were performed on 
free-floating brain sections. The markers selected were as follows: 1) neurofilament 
as a neuronal marker; 2) glial fibrillary acidic protein (GFAP) as an astrocytic marker; 
and 3) ionized calcium binding adaptor molecule 1 (Iba-1) as a marker for 
macrophages and microglia. Primary antibodies are listed in Table 5, secondary 
antibodies in Table 6. 
Table 5. Primary antibodies for immunohistochemistry on brain sections. 
Antibody Dilution Species Manufacturer 
Neurofilament 1:1000 mouse Abcam, Cambridge, UK 
GFAP 1:250 rabbit DAKO, Glostrup, Denmark 
Iba-1 1:1000 rabbit Wako, Richmond, VA, USA 
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Table 6. Secondary antibodies for immunohistochemistry on brain sections. 
Antibody Dilution Species Manufacturer 
Anti-rabbit 
Alexa488 
1:300 donkey Invitrogen, Darmstadt, Germany 
Anti-mouse 
Alexa488 
1:300 donkey Invitrogen, Darmstadt, Germany 
 
Brain sections were taken up during cutting in a freezing buffer and then stored at -20 
°C in the dark. For immunohistochemistry, all incubation steps were performed in a 6-
well plate on a shaker to ensure optimal distribution of the reagents over the entire 
surface and among all brain sections. The minimal required volume was 0.5 ml per 
well. All steps were performed in the dark and after wrapping the vessel in aluminium 
foil. Brain sections were washed three times for 10 min in PBS and then blocked in 
10 % goat serum and 1 % triton in PBS for 1 hour at RT. Then sections were 
incubated with primary antibodies in 1 % goat serum and 0.3 % triton in PBS 
overnight at RT or for 2 days at 4 °C. After three washing steps of 10 min each in 
PBS, the sections were incubated with the secondary antibody coupled to Alexa488 
(green, so as to not overlap with the red signal from the fluorophore-coupled NPS) 
diluted in the same solution as for the primary antibody. The sections were then 
washed six times with PBS for 15 min per washing step; DAPI was included in the 
fourth washing step. For mounting, the sections were transferred to a box filled with 
double distilled H2O (ddH2O) and mounted on the slides using a thin brush. 
Image acquisition was performed using either an epifluorescence or a confocal 
microscope. 
2.3. Analysis of behavioral and molecular effects of intranasal NPS application 
2.3.1. Animals 
For behavioral experiments after intranasal NPS application and for the mouse model 
of PTSD, 6 weeks old male C57BL/6N mice were purchased from Charles River and 
allowed to habituate until they were 10 weeks old, at which time-point the 
experiments started. Male 10 weeks old HAB mice were obtained from the breeding 
facility of the MPI of Biochemistry, Martinsried. The mice that underwent the PTSD 
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paradigm were housed in groups of 4 mice per cage; all other mice were housed 
singly. All experiments were approved by the Government of Upper Bavaria and 
were in accordance with European Union Directive 86/609/EEC. 
2.3.2. Intranasal NPS application in C57BL/6N and HAB mice 
Two mouse groups were used for each experiment. A control group was mock-
treated with the NPS solvent (vehicle treatment) and a treatment group received the 
active substance. 
Native rat NPS diluted in Ringer solution was applied intranasally in the alert mice 
which were restrained manually during application in a supine position with the head 
fixed in a position of approximately 45 degrees to the body (see Figure 7). The 
application was performed as in the case of Cy3-NPS (2.2.3.), allowing a 5 min break 
to avoid exhalation and overfilling of the nostrils, as well as reduced or delayed 
absorbtion. Mice were held immobile for 10 seconds after substance application until 
all the substance had been absorbed. Substance exhalation was carefully monitored 
during and after application and was found to be minimal to non-occurring.  
 
Figure 7. Intranasal treatment in alert mice restrained manually. 
To determine the optimal NPS dose for eliciting behavioral effects after intranasal 
application, the C57BL/6N mice received 7, 14 and 28 nmol of substance per mouse. 
The HAB mice then received the dose that had been determined to be optimal in this 
first assay, which was 14 nmol per mouse.  
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2.3.2.1. Behavioral assays 
The mice were tested 4 hours after application. The question of interest was whether 
intranasal application of NPS has the same anxiolytic effects as described by others 
for ICV injection. However, since it is very difficult to distinguish between increased 
locomotion and reduced anxiety, parameters that relate to both these aspects were 
examined in each test. 
The mice were tested in three different assays performed in the following order: open 
field, dark-light box and EPM (for an overview of the experimental timeline see Figure 
22). Each test lasted for 5 min, with a 5 min interval between single tests. The open 
field, which consists of an open round arena, was performed first to obtain a baseline 
of locomotion as measured by the total distance traveled. If there are no differences 
in locomotion in the open field, it can be safely assumed that the treatment had no 
effect on locomotion. To double-check, locomotion-related indices were also 
investigated in the subsequent anxiety tests. The principle of the dark-light box, 
which consists of two chambers (a small black and dark one and a white, brightly lit 
larger one, connected by a single passage), relies on the fact that mice naturally 
prefer darker environments where they feel more protected from potential predators. 
On the other hand, mice also like to explore new environments, an aspect which is 
taken into account by making the “risky” light chamber larger. Reduced anxiety will 
be mirrored by an increased percentage of time spent in the light chamber. To 
characterize possible changes in locomotion, the percent distance traveled in the 
light chamber was also compared between vehicle and NPS treatment. Finally, in the 
EPM, a plus-shaped platform elevated at ca. 1 m above the floor and consisting of 
two open and two closed arms (described in detail in 1.6.2.), the percent time spent 
on the open arm served as a measure of anxiety, while the number of entries into the 
closed arms was taken as a reliable indicator of locomotion. The animals’ behavior 
during testing was videotaped and relevant parameters were analyzed with the 
tracking software ANY-maze version 4.30. 
2.3.2.1.1. Statistical analysis 
The data was analyzed using one-way analysis of variance (ANOVA) with 
Bonferroni’s post hoc test in the case of the C57BL/6N mice and two-tailed unpaired 
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t-test for the HAB mice. Outliers were excluded using Grubbs’ test. p-values between 
0.1 and 0.05 were considered to represent a trend, p-values below 0.05 were 
considered significant.  
2.3.2.2. Analysis of molecular changes after NPS treatment 
2.3.2.2.1. Preparation of single brain regions and selection of candidates 
To better characterize the changes elicited by NPS treatment in protein expression 
(which had not been described until now), especially such changes as might shed 
light on the anxiolytic mechanisms of NPS, two brain regions that have been strongly 
linked to anxiety and fear formation and extinction were chosen: the hippocampus 
(Hc) and the prefrontal cortex (Pfc). In these brain regions, candidates involved in the 
glutamatergic system and in synaptic plasticity were selected for investigation 
following a hypothesis-driven approach, since both NPS effects and the pathological 
processes of anxiety disorders have been associated with these systems. These 
candidates were: subunits 1 and 2 of the AMPA receptor (GluR1 and GluR2); the 
astrocytic glutamate transporter (Glt-1); and isoforms I and II of synapsin. Changes in 
expression levels of these candidates were examined on the mRNA as well as on the 
protein level. The single brain regions were prepared on ice from the freshly isolated 
brain. For subsequent total mRNA isolation, the brain regions were isolated 4 hours 
after treatment, since changes on the transcriptional level are very fast, preserved in 
RNase-free 2 ml tubes and shock-frozen in liquid nitrogen. For protein isolation, the 
brain regions were isolated 24 hours after treatment, to allow time for effects on the 
protein level to materialize, shock-frozen in methylbutane (pre-cooled and stored on 
dry ice) and then kept in 2 ml tubes. All samples were stored at -80 °C. 
2.3.2.2.2. mRNA isolation and real-time PCR 
mRNA was isolated as described in detail in 2.1.1.1. and then reverse transcribed 
into cDNA as described in 2.1.1.2.. For evaluation of candidate mRNA expression, 
real-time PCR was performed. The QuantiFast SYBR Green PCR Kit was used 
according to the manufacturer’s instructions. In brief, 5 µl QuantiFast Mix were mixed 
with 1 µl forward and 1 µl reverse primer from a stock of 5 pmol/µl and with 1 µl H2O, 
the master mix was pipetted into glass capillaries and then 2 µl cDNA were added. 
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Before real-time PCR, the samples were centrifuged briefly. The real-time PCR 
settings used were as follows:  
1. initial denaturation: 95 °C – 10 min 
2. denaturation: 95 °C – 10 seconds 
3. annealing + elongation: 60 °C – 30 seconds 
 
A melting curve was generated at the end of every run to ensure the quality of the 
PCR product. Crossing points (Cp) were calculated automatically using the absolute 
quantification fit points method. Relative gene expression was determined by the 2-
ΔΔC
T method (Livak and Schmittgen, 2001). Cp values were normalized to expression 
levels of the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase 
Gapdh. Primers designed by others were used for Glt-1 (Perisic et al., 2010), GluR1 
and GluR2 (Blanco et al., 2011). Self-designed primers are shown in Table 7. 
Table 7. Real-time PCR primers for synapsin I and II and Gapdh. 
Gene of interest Forward primer Reverse primer 
Synapsin I 5’-CACCGACTGGGCAAA ATACT-3’ 
5’-TCCGAAGAACTTC 
CATGTCC-3’ 
Synapsin II 5’-CCTTCATCGACGCCA AGTAT-3’ 
5’-GAGCAGGCATCTAC 
CCAGAG-3’ 
Gapdh 5’-CCATCACCATCTTC CAGGAGCGAG-3’ 
5’-GATGGCATGGACTGT 
GGTCATGAG-3’ 
 
2.3.2.2.2. Protein isolation and immunoblotting 
A protease inhibitor cocktail was freshly added at 1x final concentration to 
homogenization and extraction buffer before use. 100 µl homogenization buffer were 
added to each brain tissue sample and the tissue was homogenized thoroughly with 
the turrax. An equal amount of extraction buffer was added and the lysate 
subsequently sonicated thirty times. The samples were then centrifuged at 13 krpm 
for 5 min at RT to spin down the debris and the supernatant was transferred into a 
new tube. This lysis method does not open the nucleus; the lysate therefore contains 
exclusively cytosolic and membranary protein fractions. 
Protein concentration was determined using the BCA Protein Assay Reagent 
(bicinchoninic acid) according to the manufacturer’s instructions. In brief, a BSA 
40 cycles 
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standard in water was prepared with descending protein concentrations: 2 mg/µl, 1.5 
mg/µl, 1 mg/µl, 0.75 mg/µl, 0.5 mg/µl, 0.25 mg/µl, 0.125 mg/µl, 0.025 mg/µl and 0 
mg/µl. The BCA working reagent was made by mixing BCA Reagent A with Reagent 
B at a ratio of 50:1. 200 µl working reagent were pipetted per well of a 96-well plate 
and 25 µl of the standards and subsequently of the samples were added. The plate 
was incubated in the dark at 37 °C for 1 hour to allow for development of the 
colorimetric reaction. In an alkaline medium, proteins reduce Cu2+ to Cu1+; BCA 
forms a complex with Cu1+, which leads to development of a violet-colored 
compound, the intensity of which is proportional to the protein concentration in the 
sample. Absorbance was then measured at 562 nm in a plate reader. Protein 
samples were then adjusted to a concentration of 2 µg/µl for loading on the gel. The 
dilutions were made with dH2O containing protease inhibitor cocktail at 1x 
concentration and with Laemmli buffer and then inactivated for 10 min at 95 °C. 
For immunoblotting, proteins were loaded on gels and separated by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Each gel consisted of a 
separation gel (lower part) and a stacking gel containing the wells (upper part). For 
the stacking gel the solution contained 25 % lower Tris buffer, 1 % of 20 % SDS, 30 
% acrylamide at the desired concentration for the needed gel percentage, dH2O up to 
the desired volume (25 ml solution sufficient for 4 gels), and initializing factors for the 
polymerization: 0.26 % of 10 % ammonium persulfate (APS) and 0.26 % 
tetraethylmethylenediamine (TEMED). The gel was cast between two glass plates 
and the solution was covered with isopropanol in order to avoid bubble formation and 
unevenness. After the gel had solidified, all traces of isopropanol were discarded and 
the stacking gel was cast. The stacking gel consisted of 23 % upper Tris buffer, 1 % 
of 20 % SDS, 13 % of 30 % acrylamide, dH2O up to the desired volume (10 ml 
solution sufficient for 4 gels), and initializing factors for the polymerization: 0.25 % of 
10 % APS and 0.25 % TEMED. The stacking gel was then cast on top of the 
separation gel and the comb was inserted to create the wells (15 wells per gel, 
maximal volume per well: 20 µl). After the stacking gel had polymerized, the gels 
were either used immediately or stored at 4 °C wrapped in wet towels for up to one 
week. For loading, gels were placed in Laemmli running buffer and loaded with equal 
amounts of the samples, including a protein marker ranging between 170 kDa and 25 
kDa. The electrophoresis was performed first at 80 V, until the proteins had passed 
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the edge between stacking gel and separation gel (ca. 20 min) and then at 120 V for 
as long as deemed necessary for optimal separation (ca. 90 min). During the blotting 
process, proteins were transferred from the gel to a nitrocellulose membrane. Gel 
and membrane overlapped and were wrapped in two layers of filter paper and two 
layers of sponge on each side. Blotting was performed in WetBlot Buffer at 400 mA 
for 1 hour. To check for adequate protein transfer, the membranes were stained in 
Ponceau solution to unspecifically stain all proteins. Excess Ponceau was washed off 
in dH2O and the membranes were then blocked in 5 % milk solution in Tris-buffered 
saline with Tween 20 (TBST) for 1 hour at RT on a shaker at 30 rpm. Membranes 
were then incubated with the primary antibody diluted in 2.5 % milk in TBST for up to 
48 hours at 4 °C on a shaker at 30 rpm. Excess antibody was washed off in three 
washing steps of 10 min each in TBST on a shaker at 70 rpm and membranes were 
then incubated in secondary antibody coupled to horseradish peroxidase (HRP), 
diluted as described for the primary antibody, for 1 hour at RT on a shaker at 30 rpm. 
After three more washing steps, membranes were incubated in a self-made HRP 
substrate solution for 1 min on a shaker at 30 rpm to initiate the luminescence 
reaction, which was then detected on X-ray films in a dark room using an automated 
developing machine. Primary antibodies are listed in Table 8, secondary antibodies 
in Table 9. 
Quantification of protein expression was performed by quantification of the pixel 
density of the protein bands on digitalized films using ImageJ software. Protein 
expression was normalized to the housekeeping protein GAPDH. 
Table 8. Primary antibodies for immunoblotting. 
Antibody Dilution Species Manufacturer 
GluR1 1:100 goat Santa Cruz Biotechnologies, Santa Cruz, CA, USA 
GluR2 1:100 goat Santa Cruz Biotechnologies, Santa Cruz, CA, USA 
Glt-1 1:100 goat Santa Cruz Biotechnologies, Santa Cruz, CA, USA 
synapsin 1:2000 rabbit Synaptic Systems, Göttingen, Germany 
GAPDH 1:2000 mouse Santa Cruz Biotechnologies, Santa Cruz, CA, USA 
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Table 9. Secondary antibodies for immunoblotting. 
Antibody Dilution Species Manufacturer 
Anti-goat 1:10000 donkey Santa Cruz Biotechnologies, Santa Cruz, CA, USA 
Anti-mouse 1:25000 goat Sigma-Aldrich, St Louis, MA, USA 
Anti-rabbit 1:7500 goat Sigma-Aldrich, St Louis, MA, USA 
 
2.3.2.2.3. Statistical analysis 
Normalized data from real-time PCR and immunoblotting were analyzed using the 
two-tailed unpaired t-test. p-values between 0.1 and 0.05 were considered to 
represent a trend, p-values below 0.05 were considered significant. 
2.3.3. Intranasal NPS application in a mouse model of PTSD 
2.3.3.1. Behavioral assays 
The PTSD mouse model is based on administration of a strong electrical foot-shock 
(1.5 mA) considered equivalent to trauma in humans. This shock is administered in a 
rectangular shock context containing a grid. As shown previously, the development of 
the PTSD-like phenotype reaches a maximum at day 28 post-shock and persists in 
the long-term until at least as late as day 60 (Siegmund and Wotjak, 2007; Golub et 
al., 2011). To investigate the curative effects of intranasal NPS treatment on the full-
blown PTSD pathology, shocked mice were divided into two groups: mock-treatment 
with Ringer solution (vehicle) and treatment with 8 nmol NPS in Ringer solution as 
described above (2.3.2.). Treatment was performed 2 hours before behavioral 
testing. This time-point was chosen earlier than the previously used one (4 hours, 
2.3.2.1.) in the hope that the behavioral effects would be even more marked earlier 
on. Three behavioral tests were performed on three consecutive days to test for 
specific symptoms of the PTSD-like phenotype and acute NPS treatment was 
performed 2 hours before each test. First, the freezing behavior in the shock context 
was measured to check for fear expression to trauma-specific cues. For this purpose, 
mice were placed in the conditioning context (described above) and their freezing 
behavior was scored for 3 min, freezing being defined as no further movement of the 
mouse (Siegmund and Wotjak, 2007). Second, to test for social interaction, which 
has been shown to be strongly decreased in PTSD patients, mice were kept in their 
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home cage (placed in a sound-isolated cubicle), allowed to habituate for 3 min and 
then exposed to a similarly treated interaction partner, who represented the control 
(vehicle was always paired off with vehicle and NPS treatment was always paired off 
with NPS treatment). Social interaction was described as sniffing, licking, close 
following and allogrooming (cleaning the control partner’s body), whereas avoidance 
of social interaction was defined as escaping to the other end of the cage and 
keeping the approaching interaction partner at bay in an upright position with lifted 
paws (Siegmund and Wotjak, 2007). These two parameters were scored for 4 min. 
Finally, to test for hyperarousal, the startle reflex, which is highly increased in PTSD 
patients, was quantified. In this case, the acoustic startle reflex was measured: mice 
were exposed to 4 different startle stimuli (white noise, duration: 20 ms) of growing 
intensity (75 dB, 90 dB, 105 dB and 115 dB), 15 seconds apart, and the startle 
response was measured (Golub et al., 2011).  
2.3.3.2. Protein and mRNA expression in Hc and Pfc 
Brain regions (Pfc and Hc) were isolated as described above (2.3.2.3.1.) 24 hours 
after the last treatment. The same candidates were examined on mRNA and protein 
levels by real-time PCR and immunoblotting, respectively (2.3.2.3.1.-3.). 
2.3.3.3. Measurement of corticosterone plasma levels 
Trunk blood was isolated from the decapitated mice 24 hours after the last treatment, 
between 09:00 a.m. and 12:00 a.m., and collected in tubes containing EDTA to 
prevent clotting. The samples were then centrifuged at RT, 8000 rpm, for 10 min, to 
separate plasma from cell pellet. The plasma was then transferred into a new tube 
and stored at -20 °C. 
Corticosterone plasma levels were measured using the Corticosterone (Rat/Mouse) 
solid phase enzyme-linked immunoabsorbent assay (ELISA) kit according to the 
manufacturer’s instructions. The ELISA was based on the principle of competitive 
binding. In brief, after all reagents had reached RT, 10 µl of calibrator solutions C0-
C5 containing increasing corticosterone concentrations (0 – 15 – 50 – 185 – 640 – 
2250 ng/ml) and of each sample were pipetted into separate wells into a 
microtiterplate containing wells coated with polyclonal rabbit anti-corticosterone 
antibody; measurements were performed in duplicates. 100 µl incubation buffer per 
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well were then added, followed by 50 µl per well of enzyme conjugate containing 
HRP-coupled corticosterone. After 2 hours incubation at RT on a microplate mixer, 
the content of the wells was discarded and the wells were rinsed 4 times with 300 µl 
1x washing solution per well. 200 µl of substrate solution containing 
tetramethylbenzidine (TMB) and H2O2 were added to each well and the plate was 
incubated for 30 min in the dark; the reaction was subsequently stopped by addition 
of 50 µl stop solution to each well. The absorbances of the wells’ content were then 
measured at 450 nm in a microplate reader.   
2.3.3.4. Statistical evaluation 
All statistical evaluations were performed using GraphPad Prism 5.03. 
2.3.3.4.1. Behavioral assays 
The % freezing for context-specific fear was compared between the two groups using 
the two-tailed unpaired t-test. The % social interaction was similarly compared 
between the two groups using the two-tailed unpaired t-test. For evaluation of the 
acoustic startle response (ASR), the response intensity was compared between the 
two groups using a two-way ANOVA with group (vehicle vs. NPS) as one factor and 
tone-pitch (75 dB, 90 dB, 105 dB and 115 dB) as the second factor, followed by 
Bonferroni’s post hoc test. 
2.3.3.4.2. Protein and mRNA data 
Expression levels of protein and mRNA were compared between the two groups 
using the two-tailed unpaired t-test (see 2.3.2.3.3.). 
2.3.3.4.3. Corticosterone plasma levels 
A standard curve was plotted on a semi-log plot using the calibrator concentrations in 
ng/ml (X values) and the corresponding assay results (the measured absorbances, Y 
values) as reference points. As the value 0 cannot be plotted on a semi-log plot, the 
zero-concentration X value was approximated using 1.0e-003, which is two log units 
below the lowest non-zero X value, in order to plot the top of the curve as accurately 
as possible. All X values were subsequently log transformed. The curve was then fit 
according to a nonlinear regression and sigmoidal dose-response with variable slope. 
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The unknown X values corresponding to the corticosterone concentrations in the 
samples were then interpolated from the fitted curve and reverse-transformed from 
the log values to obtain the corticosterone concentrations in ng/ml. The mean 
corticosterone concentration values were compared between vehicle and treatment 
groups using the two-tailed unpaired t-test.    
2.4. Behavioral effects of NPS treatment via injection into the ventral CA1 
region (vCA1) 
2.4.1. Stereotactic surgery 
Stereotactic surgery was performed as described above (2.2.2.). Guide cannulas 
were implanted at the following coordinates: 3.1 mm posterior and ± 3 mm lateral 
from the bregma, and 2 mm ventral from the skull surface. For behavioral 
experiments, animals were implanted bilaterally; for injection of Cy3-NPS 
implantation was performed unilaterally. 
2.4.2. Injection of Cy3-NPS into vCA1 
Cy3-NPS was administered unilaterally at a concentration of 0.01 nmol/µl and in a 
total volume of 0.7 µl (solvent: Ringer solution) as described above (2.3.2.). Brains 
were removed and cryosections were collected and counterstained with DAPI as 
described above (2.2.4.). 
2.4.3. Behavioral assays 
Mice were injected bilaterally either with 0.1 nmol native rat NPS in a total volume of 
0.5 µl for each side (solvent: Ringer solution) (treatment group) or with 0.5 µl of 
Ringer solution for each side (vehicle group). 30 min after injection, three behavioral 
assays (open field, dark-light test and EPM) were performed sequentially in the order 
mentioned, as described previously (2.3.2.1.). 24 hours after the behavioral assays, 
mice were injected bilaterally with fluorescein, which emits a green signal upon 
stimulation and can therefore be seen very well in brain sections. Mice were 
immediately sacrificed afterwards and the locations of the guide cannulas were 
checked in histological cryosections of 40 µm counterstained with DAPI (see above). 
Mice with deviating injection sites were excluded from all further analysis.  
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2.4.3.1. Statistical analysis 
Statistical analysis was performed using the two-tailed unpaired t-test. 
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3. Results 
3.1. Cloning of NPSR and in vitro analysis of NPSR-NPS interaction  
In order to characterize the behavior of NPSR upon NPS binding, constructs of the 
murine NPSR were generated that allow tracking of the receptor upon expression in 
cell culture. The experiments were performed with two different constructs, i.e. 
EGFP-NPSR and NPSR-FLAG (see Figure 8).  
 
 
Figure 8.  Cloning strategy of tagged NPSR constructs. A In pEGFP-C1, NPSR was inserted 
after the EGFP-sequence. B In pcDNA 3.1 (-), the FLAG-tagged NPSR sequence 
was inserted. PCMV: cytomegalovirus promoter. KanR/AmpR: kanamycin/ampicillin 
resistance gene. MCS: multiple cloning site. 
In the EGFP-NPSR construct, NPSR was coupled N-terminally to enhanced green 
fluorescent protein (EGFP) to allow for direct tracking by microscopy imaging without 
additional stainings. In the NPSR-FLAG construct, the FLAG tag was attached C-
terminally to NPSR, in order to rule out that the interaction between NPSR and EGFP 
may influence the behavior of the receptor. NPSR-FLAG was visualized by 
immunofluorescent stainings against the FLAG tag. A fluorescent NPS conjugate 
(Cy3-NPS) was used for stimulation of cells transfected with the receptor constructs 
to allow for visualization of their interaction. All experiments were performed in HEK 
cells, since they are the most commonly used cell line for initial characterization of 
constructs and have been previously used for investigation of human and murine 
NPSR distribution (Bernier et al., 2006). 
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3.1.1. Visualization of EGFP-NPSR and FLAG-NPSR in HEK cells 
Gel electrophoresis of NPSR amplification products with specific primers in cDNA 
from HEK cells showed that NPSR mRNA is expressed specifically in HEK cells 
transiently transfected with plasmids containing EGFP-NPSR and NPSR-FLAG 
(Figure 9A, B). No NPSR expression was detected by this method in HEK cells either 
transfected with the empty cloning vector or untransfected (Figure 9A, B). Control 
actin amplification confirmed that similar amounts of cDNA were present in all 
investigated samples (Figure 9A). 
 
Figure 9. Cloning and expression of NPSR constructs. A 3 % TBE agarose gel showing 
PCR products actin and NPSR from cDNA of HEK cells transfected with NPSR in 
pcDNA3.1 (-) and untransfected. Predicted band weight: NPSR = 1125 bp; actin = 
270 bp. B 3 % TBE agarose gel showing PCR product NPSR amplified from 
cDNA of HEK cells transfected with NPSR-FLAG in pcDNA3.1 (-) and 
untransfected. Predicted band weight: NPSR = 1125 bp. C EGFP-NPSR (green) 
expression in HEK cells as compared to EGFP expression in HEK cells 
transfected with pEGFP-C1. Image taken with an epifluorescence microscope in 
live cells at 20x magnification. Scale bars, 40 μm. D Immunostaining against 
FLAG (green) in HEK cells expressing NPSR-FLAG. Nuclear staining: DAPI 
(blue). Image taken with a confocal microscope at 60x magnification. Scale bar, 
20 μm. 
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Epifluorescence and confocal microscopy of living and fixed cells revealed that the 
tagged NPSR constructs are also well expressed at the protein level (Figure 9C, D). 
Both constructs were expressed cytosolically as well as at the membrane, which 
coincides with results obtained by others after immunostaining of HEK cells 
expressing hemagglutinin (HA)-tagged NPSR in permeabilized and non-
permeabilized cells (Bernier et al., 2006). There were significant differences in the 
amount of expressed protein between HEK cells transfected with EGFP-NPSR and 
those transfected with the empty pEGFP-C1 vector (Figure 9C). While EGFP was 
very strongly expressed throughout the cell with no significant differences between 
compartments, EGFP-NPSR had a lower expression intensity and was comparably 
more highly expressed at the cell membrane. NPSR-FLAG, visualized by 
immunostaining of FLAG on PFA-fixed cells, showed the membranary distribution of 
the receptor even more clearly (Figure 9D).  
3.1.2. Stimulation of NPSR-expressing HEK cells with Cy3-NPS 
To investigate the behavior of receptor-ligand complex after ligand stimulation, Cy3-
NPS was added to HEK cells expressing EGFP-NPSR. 10 min after ligand addition, 
Cy3-NPS had already bound to its receptor in a highly specific manner, as revealed 
by colocalization of red and green signals, and the receptor-ligand complex was 
internalized into the cells (Figure 10). There, it accumulated into cytoplasmic and 
perinuclear vesicles, as shown previously for other neuropeptides upon binding to 
their GPCRs (Grady et al., 1995).   
 
Figure 10. HEK cells transiently transfected with EGFP-NPSR (green) after 10 min of 
incubation with Cy3-NPS (red) (adapted from (Ionescu et al., 2012)). Nuclear 
staining: DAPI (blue). Rightmost panel depicts an overlay of all three channels 
and shows colocalization of Cy3-NPS and EGFP-NPSR (yellow) in cytoplasmic 
(arrows) and perinuclear (arrowheads) vesicular structures. All images were 
taken with a confocal microscope. Scale bars, 20 µm. 
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These results were confirmed also for FLAG-NPSR (Figure 11), confirming that the 
specific behavior observed here is not due to any interaction of the receptor with the 
quite large EGFP. 
In order to better characterize the rough dynamics of this process, HEK cells 
expressing FLAG-NPSR were stimulated with Cy3-NPS (Figure 11). A timeline of 
receptor-ligand internalization showed that immediately after ligand addition (0 min), 
Cy3-NPS bound to the receptor at the cell membrane and created an overlapping 
outline of the cell surface. At 10 min, the receptor-ligand complex had for the most 
part been internalized into the cell in small cytoplasmic vesicles, and the receptor 
fraction at the membrane was depleted in comparison with the previous time-point. At 
30 min, Cy3-NPS and some of the receptor to which it had bound had mostly 
accumulated in a large perinuclear vesicle, with only a few smaller vesicles still 
present in the rest of the cytoplasm; the receptor presence at the membrane had 
been restored almost completely to the initial state. 
 
Figure 11. Timeline of Cy3-NPS internalization in HEK cells expressing NPSR-FLAG at 3 
different time-points: 0 min, 10 min and 30 min after Cy3-NPS addition. Nuclear 
staining: DAPI (blue). Immunostaining against FLAG: green. Cy3-NPS: red. All 
images were taken with a confocal microscope. Scale bars, 20 μm. 
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These results showed fluorescently labeled NPS to be appropriate for tracking at 
single-cell resolution interactions with the receptor and intracellular internalization in 
cell culture. 
3.2. Brain target regions and target neurons of NPS 
Therefore, relying upon the above results obtained in cell culture, Cy3-NPS was used 
here for investigating the intracerebral distribution pattern in vivo after intranasal 
delivery. Since, as described previously in detail (see 1.5.), targeting the CNS after 
intranasal administration is dependent upon many factors, such as size and polarity 
of the molecule under investigation, this approach served to establish for the first 
time the feasibility of intranasal delivery in the case of NPS. Fluorophore-conjugated 
NPS was used because the radioactively labeled ligands employed so far for intra-
CNS tracking after intranasal administration have a very low spatial resolution that 
enables localization only to brain regions and not to single cells or subcellular 
compartments (Thorne et al., 2004).  
First, in vivo tracking of this substance was investigated using intracerebroventricular 
(ICV) injection, an established method for brain delivery into mice; this experiment 
was then reproduced for intranasal application. The hypothesis underlying these 
experiments was that Cy3-NPS will become distributed evenly throughout all cerebral 
structures upon reaching the brain and will accumulate specifically in cells expressing 
NPSR via internalization of the receptor-ligand complex. 
3.2.1. Identification of brain target regions and cells of NPS by 
intracerebroventricular (ICV) administration of Cy3-NPS 
In order to check whether the NPSR-dependent intracellular internalization of Cy3-
NPS observed in cell culture also works in vivo, Cy3-NPS was delivered to the brain 
first by ICV injection. 
At 30 min after unilateral ICV administration of Cy3-NPS, the substance had 
distributed throughout the brain and uptake within single cells in specific brain 
regions had occurred. A complete overview of brain regions where cells took up Cy3-
NPS is available in Table 10. 
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Table 10. Overview of brain regions targeted by Cy3-NPS. 
 
Forebrain 
        Accumbens nucleus 
        Anterior olfactory area, ventral part 
        Anterior olfactory area, external part
Basal ganglia 
         Globus pallidus 
Cerebral cortex 
         Primary motor cortex 
         Secondary motor cortex 
         Somatosensory cortex 
         Cingulate cortex, area 1 
         Endopiriform cortex 
Amygdala 
          Medial amygdaloid nuclei 
          Anterior cortical amygdaloid nuclei 
          Posterior cortical amygdaloid 
              nuclei 
          Basolateral amygdala 
          Central amygdala 
          Lateral amygdala 
          Bed nucleus of the stria terminalis  
              (intraamygdaloid division) 
          Amygdalohippocampal area 
Hippocampus 
           Dentate gyrus 
           CA1 
           CA2 
           CA3 
           Ventral hippocampus, granular 
              layer of dentate gyrus  
 
Thalamus 
          Medial habenula 
          Lateral habenula 
          Paraventricular thalamic nucleus 
          Mediodorsal thalamic nucleus 
Hypothalamus 
         Arcuate nucleus 
         Paraventricular nucleus 
         Dorsomedial nucleus 
         Ventromedial nucleus 
         Periventricular nucleus  
         Suprachiasmatic nucleus  
Preoptic area 
         Median preoptic nucleus 
         Ventromedial preoptic nucleus 
         Vascular organ of the lamina       
              terminalis 
Midbrain and brainstem areas 
          Dorsal raphe 
          Posterodorsal tegmental nucleus 
          Periaqeductal gray 
          Central gray of the pons 
          Red nucleus 
          Locus coeruleus 
          Barrington’s nucleus 
          Medial parabrachial nucleus 
          Medial vestibular nucleus 
Cerebellum 
           Purkinje cells     
 
Cell populations containing Cy3-NPS were identified in regions associated with 
stress-response and learning such as the lateral habenula and the mediodorsal 
thalamic nuclei, respectively (Figure 12B), as well as in regions with neuroendocrine 
function, such as the arcuate and ventromedial hypothalamic nuclei (Figure 12C). 
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Figure 12.  Representative selection of mouse brain regions targeted by ICV-administered 
fluorescent Cy3-NPS (Ionescu et al., 2012). A-D Leftmost panels show a 
schematic overview of murine brain regions (Franklin and Paxinos, 2007). 
Middle panels show nuclear counterstain DAPI (blue) (scale bar, 100 µm) and 
cell populations having taken up Cy3-NPS (red). The images in the red channel 
are presented in two different magnifications (scale bars, 100 µm and 10 µm) – 
white rectangles indicate area of magnification. Rightmost panels show an 
overlay of the blue and red channels (scale bar, 100 µm). A Cortical structures: 
primary somatosensory cortex (S1). B Thalamic structures: paraventricular 
thalamic nucleus (PV), sporadically in medial habenula (MHb), lateral habenula 
(LHb), mediodorsal thalamic nucleus (MD): medial (MDM), central (MDC) and 
lateral (MDL). Third ventricle (3V). C Hypothalamic structures: periventricular 
hypothalamic nucleus (Pe), dorsomedial hypothalamic nucleus (DM), 
ventromedial hypothalamic nucleus (VMH), arcuate hypothalamic nucleus (Arc). 
Third ventricle (3V). D Brainstem structures: central gray of the pons (CGPn), 
medial vestibular nucleus (MVe), sporadically in posterodorsal tegmental 
nucleus (PDTg), Barrington’s nucleus (Bar), sporadically in locus coeruleus (LC) 
and in medial parabrachial nucleus (MPB). Fourth ventricle (4V). All images 
were acquired with a confocal microscope and are representative for a total of 
10 mice. See Table 10 for a complete list of brain regions where uptake of Cy3-
NPS was detected. 
Most interestingly, Cy3-NPS uptake was detected also in regions farther away from 
the cerebroventricular system, for instance in cortical regions (Figure 12A), and in 
very caudal brain regions like the locus coeruleus, the tegmental nucleus, 
Barrington’s nucleus and the parabrachial nucleus (Figure 12D). Even in the 
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cerebellum, which is distant from both the ventricular system and the injection site, 
single cells were found to contain Cy3-NPS (Figure 13). This data proves that ICV 
administration of Cy3-NPS is capable of targeting the entire murine brain, not only 
regions close to the ventricular system. 
 
Figure 13.  Representative image of Cy3-NPS uptake in neurons of the cerebellum after ICV 
injection. Upper panel shows schematic overview and Nissl staining of the brain 
section (Franklin and Paxinos, 2007). Crus1: crus 1 of the ansiform lobule. 4V: 
fourth ventricle. Images were taken with a confocal microscope at 10x 
magnification. Scale bars, 100 µm. 
 
3.2.2. Specificity of Cy3-NPS uptake 
In order to ascertain that the observed Cy3-NPS uptake is specific for the unlabeled 
neuropeptide and dependent upon NPSR expression at the cell membrane, various 
control experiments were performed. 
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Figure 14.  Intracerebral distribution of Cy3-NPS and rhodamine-NPS shown here 
exemplarily in two brain regions 30 min after ICV delivery of substance 
(leftmost panels: overview images, Franklin and Paxinos, 2007) (Ionescu et 
al., 2012). Left panel: rhodamine-NPS (images taken with an epifluorescence 
microscope, representative for a total of 5 mice). Right panel: Cy3-NPS 
(images taken with a confocal microscope). A Third ventricle (3V). 
Hypothalamic structures: anterior parvicellular paraventricular hypothalamic 
nucleus (PaAP), ventral paraventricular hypothalamic nucleus (PaV), 
dorsolateral and ventromedial suprachiasmatic nucleus (SChDL, SChVM). B 
Optical tract (opt). Amygdaloid structures: medial posteroventral and 
posterodorsal amygdaloid nuclei (MePV, MePD), posteromedial cortical 
amygdaloid nucleus (PMCo). Scale bars, 100 µm. 
First, the distribution patterns of two different fluorescent NPS conjugates (Cy3-NPS 
and rhodamine-NPS) upon ICV injection were examined (Figure 14). Comparison of 
substance uptake in various brain regions, such as hypothalamic structures (Figure 
14A) and amygdaloid nuclei (Figure 14B), revealed identical distribution and 
internalization patterns for Cy3-NPS and rhodamine-NPS. In addition, the same 
experiment was performed to compare the distributions of Cy3-NPS and 
unconjugated rhodamine, respectively (Figure 15). As visible in an example from the 
olfactory region, Cy3-NPS is specifically internalized into certain cells, while pure 
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rhodamine distributes evenly in the brain parenchyma, forming aggregates that do 
not correspond to any cellular structure. These results prove that the uptake 
observed is dependent only upon NPS and not upon the fluorescent tag, nor upon 
the combination of NPS and fluorescent tag. 
 
Figure 15. Intracerebral distribution of unconjugated rhodamine shown exemplarily in a 
region from the olfactory bulb 30 min after ICV administration (Ionescu et al., 
2012). Images were taken with an epifluorescence microscope. Image from the 
same area 30 min after ICV administration of Cy3-NPS (left panel). Image was 
taken with a confocal microscope. Ventral and external part of the anterior 
olfactory area (AOV, AOE) (overview image, Franklin and Paxinos, 2007). Scale 
bars, 20 µm. 
Second, to prove that NPS uptake occurs via interaction with an NPS-specific binding 
partner expressed at the cell membrane, unlabeled NPS was pre-injected at fivefold 
concentration of Cy3-NPS 10 min before ICV administration of Cy3-NPS. The 
assumption was that the unlabeled NPS would saturate the binding partners and 
therefore inhibit Cy3-NPS uptake 10 min later. Since this approach does not exclude 
the existence of an additional binding partner besides the already known NPSR, two 
competitive NPSR-antagonists, the peptidergic antagonist [D-
Cys(tBu)5]Neuropeptide S (Camarda et al., 2009) and (R)-SHA68, the active 
enantiomer of SHA 68 (Okamura et al., 2008; Trapella et al., 2011), were co-injected 
with Cy3-NPS in a parallel experiment. Uptake and distribution of the fluorescent 
substance were subsequently examined. As expected, pre-injection of unlabeled 
NPS as well as co-injection with the competitive NPSR-antagonists strongly reduced 
Cy3-NPS uptake throughout the brain (Figures 16 and 17). Therefore, it can be 
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concluded that intracellular Cy3-NPS uptake is dependent upon expression of active 
NPSR at the cell membrane.  
To sum up, these control experiments indicate that by this method, it was possible to 
identify the hitherto unknown physiological target cells and target brain regions of 
NPS.  
 
Figure 16. Analysis of NPSR-dependence of Cy3-NPS uptake in vivo (adapted from 
(Ionescu et al., 2012)). From left to right: Coronal sections through mouse brain 
(overview (Franklin and Paxinos, 2007)) without and after pre-injection of native 
NPS at 5fold concentration 10 min before ICV administration of Cy3-NPS, and 
after co-injection with the NPSR antagonists [D-Cys(tBu)5]Neuropeptide S and 
(R)-SHA68 at 150fold concentration. A Posteroventral nucleus of the medial 
amygdala (MePV), cortical amygdala (ACo). Scale bars, 20 µm. B Exemplary 
image from the preoptic area comparing uptake of Cy3-NPS. Median preoptic 
nucleus (MnPO), the vascular organ of the lamina terminalis (VOLT) and the 
ventromedial preoptic nucleus (VMPO). Optic tract (opt). All images are 
representative for a total of 4 mice pre-treated with native NPS before ICV 
administration of Cy3-NPS and a total of 3 mice co-treated with the antagonists. 
Scale bars, 100 µm. All images were taken with a confocal microscope. 
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Figure 17. Uptake of Cy3-NPS after pre-injection of native NPS or NPSR antagonists 
(adapted from (Ionescu et al., 2012)). Leftmost panels show overview images of 
the respective brain regions (Franklin and Paxinos, 2007). Exemplary images of 
brain areas from murine brains having received pre-injection of native NPS at 
5fold concentration before ICV administration of Cy3-NPS or after coinjection of 
Cy3-NPS and NPSR antagonists [D-Cys(tBu)5]NPS and (R)-SHA 68 at 150fold 
concentration. A Thalamic structures (compare Figure 12B); and B 
hypothalamic structures (compare Figure 12C). Third ventricle: 3V. All images 
were taken with a confocal microscope. Scale bars, 100 µm. 
3.2.3. Characterization of cell types taking up Cy3-NPS 
As shown above, intracerebral Cy3-NPS administration is not only a valid method to 
track NPS delivery into the brain at the cellular level, but also led to identification of 
NPS target brain regions and cells. Therefore, in a next step, these cells were 
characterized with regard to their subtype. 
Cells that had internalized Cy3-NPS appeared, from a morphological point of view, 
very similar to neurons: they were larger and had fewer processes when compared to 
either astroglia or microglia. In addition, immunostainings with antibodies against 
neuronal markers (neurofilament – NF, Figure 18A) as well as against astroglial 
(GFAP, Figure 18B) and microglial markers (Iba-1, Figure 18C) revealed that the 
Cy3-NPS signal colocalizes only with the neuronal marker. 
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Figure 18.   Analysis of cell types targeted by Cy3-NPS (Ionescu et al., 2012). A Co-staining 
with the neuronal marker neurofilament (NF) (green). This representative image 
was taken from the dentate gyrus. Scale bar, 20 µm. Z-stack of 10 images in 1 
µm intervals. B Hippocampal CA3 region after co-staining with glial fibrillary 
acidic protein (GFAP) (green), an astroglial marker. Z-stack of 18 images in 1 
µm intervals. Scale bar, 20 µm. C Dentate gyrus after co-staining with the 
microglial marker Iba-1 (green). Z-stack of 19 slices in 1 µm intervals. Scale bar, 
20 µm. Cy3-NPS: red; nuclear counterstain DAPI: blue. All images were 
acquired with a confocal microscope and are representative for a total of 10 
mice. 
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These results strongly suggest that the cells taking up Cy3-NPS in a highly specific 
NPSR-dependent manner are most likely neurons. Therefore, the assumption is 
obvious that these target neurons of NPS are also the ones responsible for mediating 
NPS-elicited behavioral effects. 
3.2.4. Intranasal administration of Cy3-NPS 
Relying on this data, the next step consisted in applying Cy3-NPS intranasally and 
examining the distribution pattern in comparison to the one observed after ICV 
injection of the labeled substance. Intranasal administration of Cy3-NPS led to 
substance distribution and intracellular uptake following a pattern highly similar to 
ICV injection. Although the targeted brain regions were largely identical to the ones 
observed after ICV injection, the intensity of the Cy3-NPS signal in the single cells 
was significantly lower after intranasal instillation than after injection of Cy3-NPS 
directly into the cerebral ventricles. A comparison of the targeted brain regions and of 
the Cy3-NPS signal intensities throughout the entire brain after ICV and intranasal 
administration can be found in Table 11.  
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Table 11. Overview of brain regions targeted by Cy3-NPS comparing ICV 
and intranasal administration as regards intensity and number of 
cells having taken up Cy3-NPS (adapted from (Ionescu et al., 
2012)).    
                  
         
  ICV IN    ICV IN 
Forebrain     Thalamus     
    Accumbens nucleus ++ ++    Medial habenula +++ +++ 
    Anterior olfactory area,  
           ventral part 
++ ++    Lateral habenula +++ +++ 
    Anterior olfactory area,        
           external part 
++ ++    Paraventricular thalamic  
           nucleus 
+++ +++ 
Basal ganglia        Mediodorsal thalamic nucleus +++ +++ 
         Globus pallidus +++ -/+ Hypothalamus     
Cerebral cortex        Arcuate nucleus ++ ++ 
    Primary motor cortex +++ -/+    Paraventricular nucleus ++ ++ 
    Secondary motor cortex +++ -/+    Dorsomedial nucleus ++ ++ 
    Somatosensory cortex +++ -/+    Ventromedial nucleus ++ ++ 
    Cingulate cortex, area 1 ++ -/+    Periventricular nucleus  ++ ++ 
    Endopiriform cortex ++ -/+    Suprachiasmatic nucleus  ++ ++ 
Amygdala     Preoptic area     
    Medial amygdaloid nuclei ++ -/+    Median preoptic nucleus + + 
    Anterior cortical amygdaloid         
            nuclei 
++ -/+    Ventromedial preoptic nucleus + + 
    Posterior cortical amygdaloid       
            nuclei 
++ -/+    Vascular organ of the lamina  
           terminalis 
+ + 
    Basolateral amygdala + + Midbrain and brainstem areas     
    Central amygdala + -/+    Dorsal raphe + + 
    Lateral amygdala + -/+    Posterodorsal tegmental  
           nucleus 
+ + 
    Bed nucleus of the stria  
            terminalis  
           (intraamygdaloid division) 
+ +    Periaqeductal gray + + 
                     Central gray of the pons + + 
    Amygdalohippocampal area + +    Red nucleus + + 
Hippocampus        Locus coeruleus ++ + 
    Dentate gyrus + +    Barrington’s nucleus ++ + 
    CA1 +++ +++    Medial parabrachial nucleus + + 
    CA2 +++ +++    Medial vestibular nucleus + + 
    CA3 +++ +++ Cerebellum     
    Ventral hippocampus, granular  
            layer of dentate gyrus 
+++ +++    Purkinje cells     +++ + 
            
             
 
 
 
The Cy3-NPS uptake pattern in single cells largely corresponded to the one 
observed in cell culture upon stimulation with Cy3-NPS, especially with regard to the 
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vesicular internalization pattern (Figure 19A). Furthermore, the Cy3-NPS signal 
colocalized as expected exclusively with the neurofilament signal, showing that 
intranasal NPS application also targets only neurons (Figure 19B). Control 
experiments with intranasal rhodamine application showed a different distribution 
pattern than intranasally applied Cy3-NPS, confirming the specificity of the uptake 
after intranasal application (Figure 19C). 
 
Figure 19. Intracerebral distribution of Cy3-NPS after intranasal administration. Intraneuronal 
uptake of Cy3-NPS (red) 30 minutes after intranasal delivery shown exemplarily in 
the hippocampus. Nuclear staining: DAPI (blue). A Overview of the hippocampus 
after intranasal Cy3-NPS application. Rad: radiate layer of the hippocampus; Or: 
oriens layer of the hippocampus. White inset: Hippocampal neuron from the 
oriens layer (CA3 region), Z-stack of 10 images in 1 µm intervals. B Hippocampal 
neuron from the pyramidal layer (CA3 region) after NF staining (green). All 
images were taken with a confocal microscope and are representative for a total 
of 3 mice. C Intracerebral distribution of unconjugated rhodamine shown 
exemplarily in a region from the olfactory bulb 30 min after intranasal 
administration. Image taken with an epifluorescence microscope. Scale bars, 20 
µm. 
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In conclusion, intranasal application of Cy3-NPS demonstrates that NPS can reach 
the brain following this administration method and is internalized specifically into its 
target neurons in brain regions identified previously by ICV administration. 
3.2.5. Identification of the hippocampus as a novel target brain region of NPS  
The findings from this study also shed light on the brain regions involved in the 
anxiolytic effects of NPS. Cy3-NPS uptake was detected in the dorsal endopiriform 
cortex, as well as in the basal ganglia and in amygdaloid nuclei, most important 
among which is the basolateral amygdala, a brain region closely linked to anxiety 
regulation and associated with NPS effects in mice (Jüngling et al., 2008; Meis et al., 
2008; Fendt et al., 2010) (Figure 20). 
 
Figure 20.  Amygdaloid structures targeted by Cy3-NPS (bright white): central amygdala 
(CeA), medial amygdala (MeA), basolateral amygdala (BLA), basomedial 
amygdala (BMA). Cortical structures: dorsal endopiriform cortex (DEn). Basal 
ganglia: globus pallidus (GP). Image taken with a confocal microscope. Scale 
bar, 200 µm. Adapted from (Ionescu et al., 2012). 
Most fascinating however was the identification of the hippocampus as a novel target 
brain region of NPS. Both ICV and intranasal administration of Cy3-NPS led to 
uptake of the labeled substance in the CA1, CA2 and CA3 regions as well as in the 
dentate gyrus (Tables 10 and 11, Figure 19A and Figure 21A). Cy3-NPS was 
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internalized with high specificity into the cell bodies and throughout the processes of 
certain neuronal populations of the hippocampus (Figure 21B, C). This new finding 
immediately raises questions concerning the mechanistic role of the hippocampus in 
the NPS-dependent regulation of fear and anxiety. 
 
Figure 21.  The hippocampus as a novel target region of NPS. A Representative overview 
image of the hippocampus after ICV injection of Cy3-NPS. Scale bar, 100 µm. B 
Morphologically representative cells from the granular dentate gyrus. Granular 
dentate gyrus (GrDG), molecular dentate gyrus (MoDG). Scale bar, 20 µm. Z-
stack of 15 images in 0.59 µm intervals. C Morphologically representative cell 
from the CA3 region. Scale bar, 20 µm. Z-stack of 13 images in 0.59 µm 
intervals. All images were taken with a confocal microscope. 
 
3.3. Behavioral and molecular effects of intranasally applied NPS 
After having ascertained that intranasally applied NPS reaches and distributes 
through the mouse brain, the next step was to reproduce the anxiolytic effects seen 
after ICV administration. An additional aspect under investigation was the regulatory 
effect of NPS on protein and mRNA expression levels of selected candidates. 
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3.3.1. Behavioral phenotype after intranasal NPS application 
Since the pharmacodynamics of intranasal application are known to be very different 
from those of ICV injection (Thorne et al., 1995; Thorne and Frey, 2001), the optimal 
dosis for observing behavioral effects would most likely differ. In order to establish 
the optimal NPS dose for eliciting behavioral effects after intranasal treatment, three 
different NPS doses (7, 14 and 28 nmol) were applied intranasally in C57BL/6N mice 
and their effects were compared in three different behavioral tests: open field, dark-
light test and elevated plus maze (EPM). In view of these differences between ICV 
and intranasal administration, animals were tested at 4 hrs after intranasal 
application rather than at 30 min, as for ICV treatment (see Figure 22 for an overview 
of the experimental schedule). The time-point for behavioral testing after intranasal 
treatment was chosen according to data from literature which show that effective 
concentrations of intranasally applied substances can be detected in the CNS up to 4 
hrs after application (Thorne et al., 1995; Jansson and Björk, 2002). 
 
Figure 22. Experimental timeline: intranasal NPS application at 0 and at 5 min in alert 
C57BL/6N and HAB mice restrained manually. Behavioral testing 4 hours after 
first application: A open field, B dark-light box, and C EPM. 
The open field, performed first to obtain a baseline of locomotion, showed no 
differences in locomotion for any of the three doses between controls and treated 
mice (F2, 26 = 1.364; p = 0.2733) (Figure 23A). However, in the dark-light test, a trend 
towards decreased latency to the first entry into the light compartment (a parameter 
for measuring anxiety) was observed for animals treated with 14 and 28 nmol NPS 
(F2, 24 = 3.382; p = 0.0508) (Figure 23B). This was especially meaningful since the 
locomotion as measured in percent distance traveled in the light chamber did not 
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change (F2, 24 = 0.2080; p = 0.8136), hinting at locomotion-independent anxiolytic 
effects. Most important, clear-cut anxiolytic effects were observed in the EPM, where 
animals treated with 14 nmol NPS significantly increased their percent time spent on 
the open arm (F2, 24 = 4.127; p = 0.0288) (Figure 23C). Here again, the observed 
anxiolytic effects were locomotion-independent, as the number of entries into the 
closed arm (a reliable indicator of locomotion in the EPM) did not differ between 
groups (F2, 24 = 0.5957; p = 0.5591). 
 
Figure 23.  Behavioral effects of transnasally delivered NPS in C57BL/6N mice. C57BL/6N 
mice were tested 4 hrs after intranasal NPS treatment (7 nmol, 14 nmol and 28 
nmol) in A open field, B dark-light test (% time in the light chamber: F2, 24 = 
1.666; p = 0.2102) and C EPM. n = 10. Statistical analysis: one-way ANOVA 
with Bonferroni’s post hoc test. The data is shown as % change relative to 
control. t p < 0.1; * p < 0.05. All data are shown as mean ± s.e.m. 
These results showed 14 nmol NPS to be the optimal dose for intranasal application 
with the goal of eliciting anxiolytic effects in mice. These anxiolytic effects were 
locomotion-independent and became most evident when animals were tested 4 
hours after application. 
3. Results 
 
 
60
3.3.2. Regulatory effects of NPS on protein and mRNA expression of proteins 
involved in the glutamatergic system and synaptic plasticity 
Until now, there was no data in literature examining the regulatory effects of NPS on 
cerebral protein and mRNA expression in vivo. Therefore, candidates representing 
likely targets for NPS-mediated regulation were selected relying on publications that 
link NPS to the glutamatergic system (Han et al., 2009) and to synaptic function 
(Jüngling et al., 2008; Raiteri et al., 2009). These candidates included subunits 1 and 
2 of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor 
(GluR1 and GluR2) and the astrocytic glutamate transporter (Glt-1), as well as 
isoforms I and II of synapsin. The expression of these candidates was examined on 
both mRNA and protein levels after intranasal NPS treatment (for a complete 
overview of the experimental schedule please see Figure 24). These investigations 
were performed after treatment with 14 nmol NPS in brain regions that have been 
associated with anxiety regulation, such as the hippocampus (moreover newly 
identified in this work as a target brain region of NPS) and the prefrontal cortex. 
Furthermore, analyses were performed at two different time-points. mRNA 
expression levels were investigated 4 hours after treatment, since regulation of 
mRNA expression is usually a fast process. Protein expression levels were examined 
both 4 hours after treatment (the time-point where behavioral effects are most 
pronounced) and 24 hours after treatment, since usually, the cellular protein 
synthesis machinery is too slow to produce detectable changes in protein expression 
levels within 4 hours. 
 
Figure 24.  Overview of the experimental schedule for isolation of brain regions at 4 hours 
after treatment for mRNA isolation (subsequently analyzed by real-time PCR) 
and at 24 hours after treatment for protein isolation (subsequently analyzed by 
immunoblotting). 
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In mRNA expression, there was a trend towards decrease of Glt-1 expression in the 
hippocampus of NPS-treated mice as compared to controls (t = 1.865, df = 8, p = 
0.0992) (Figure 25A), accompanied by an increase in the prefrontal cortex (t = 4.562, 
df = 7, p = 0.0026) (Figure 25B).  
 
Figure 25. Effects of transnasally delivered NPS (14 nmol) 4 hours after application on 
mRNA levels in hippocampus (Hc) and prefrontal cortex (Pfc) of C57BL/6N 
mice. A Real-time PCR analysis of Hc lysate from C57BL/6N mice 4 hours after 
intranasal NPS treatment. GluR1: t = 1.236, df = 7, p = 0.2562; GluR2: t = 
1.242, df = 8, p = 0.2493; Synapsin I: t = 0.3580, df = 4, p = 0.7385; Synapsin II: 
t = 1.243, df = 7, p = 0.2540. B Real-time PCR analysis of Pfc lysate from 
C57BL/6N mice 4 hours after intranasal NPS treatment. GluR1: t = 0.7166, df = 
5, p = 0.5057; GluR2: t = 0.6839, df = 8, p = 0.5133; Synapsin I: t = 1.063, df = 
7, p = 0.3230. Internal expression control: GAPDH. C57BL/6N: n = 5 for each 
group. Statistical analysis: two-tailed unpaired t-test. t p < 0.1; * p < 0.05; ** p < 
0.01. All data are shown as mean ± s.e.m. 
 
As expected, there were no changes in protein levels at 4 hours after treatment in 
either the hippocampus or the prefrontal cortex (Figure 26). 
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Figure 26. Effects of transnasally delivered NPS (14 nmol) 4 hours after application on 
protein levels in hippocampus (Hc) and prefrontal cortex (Pfc) of C57BL/6N 
mice. A Immunoblot analysis of Hc lysate from C57BL/6N mice 4 hours after 
intranasal NPS treatment. GluR1: t = 1.192, df = 8, p = 0.2675; GluR2: t = 
0.657, df = 8, p = 0.5552; Glt-1: t = 0.02711, df = 8, p = 0.9790; Synapsin Ia-
b/IIa: t = 1.506, df = 6, p = 0.1828. B Immunoblot analysis of Pfc lysate from 
C57BL/6N mice 4 hours after intranasal NPS treatment. GluR1: t = 0.1030, df = 
8, p = 0.9205; GluR2: t = 0.8469, df = 8, p = 0.4217; Glt-1: t = 0.03901, df = 8, p 
= 0.9698; Synapsin Ia-b/IIa: t = 1.384, df = 6, p = 0.2038. Internal expression 
control: GAPDH (35 kDa in immunoblot excerpts). Blot excerpts show three 
representative adjacent bands of each group. The immunoblot data represent 
cumulated data from at least three independent experiments. C57BL/6N: n = 5 
for each group. Statistical analysis: two-tailed unpaired t-test. All data are shown 
as mean ± s.e.m. 
24 hours after treatment, synapsin Ia-b/IIa protein expression significantly increased 
in the hippocampus (t = 2.561, df = 8, p = 0.0336) (Figure 27A). Additionally, in the 
prefrontal cortex, NPS treatment significantly increased protein expression of GluR1 
(t = 3.219, df = 8, p = 0.0123) and Glt-1 (t = 2.561, df = 8, p = 0.0336) (Figure 27B). 
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Figure 27. Effects of transnasally delivered NPS (14 nmol) 24 hours after application on 
protein levels in hippocampus (Hc) and prefrontal cortex (Pfc) of C57BL/6N 
mice. A Immunoblot analysis of Pfc lysate from C57BL/6N mice 24 hours after 
intranasal NPS treatment. GluR2: t = 0.2798, df = 8, p = 0.7868; Synapsin Ia-
b/IIa: t = 1.549, df = 6, p = 0.1601. B Immunoblot analysis of Hc lysate from 
C57BL/6N mice 24 hours after intranasal NPS treatment. GluR1: t = 1.271, df = 
8, p = 0.2396; GluR2: t = 0.9666, df = 8, p = 0.3621; Glt-1: t = 1.628, df = 8, p = 
0.1421. Internal expression control: GAPDH (35 kDa in immunoblot excerpts). 
Blot excerpts show three representative adjacent bands of each group. The 
immunoblot data represent cumulated data from at least three independent 
experiments. C57BL/6N: n = 5 for each group. Statistical analysis: two-tailed 
unpaired t-test. * p < 0.05; ** p < 0.01. All data are shown as mean ± s.e.m. 
To sum up, behavioral effects of NPS treatment were accompanied by changes in 
mRNA expression levels; long-term NPS-elicited changes were found in protein 
expression levels. These findings demonstrate the ability of NPS to regulate 
expression of proteins associated with the glutamatergic circuit and with synaptic 
plasticity in brain regions involved in anxiety such as the hippocampus and the 
prefrontal cortex. These regulatory effects are dependent on the examined 
candidate, the brain region and the time-point after treatment and occur differentially 
on protein and mRNA levels. 
3.4. The role of the ventral hippocampus in NPS-elicited anxiolytic effects 
As described previously in this work, the hippocampus was identified as a novel NPS 
target region by ICV and intranasal administration of Cy3-NPS (see Figures 19 and 
21). Additionally, electrophysiological recordings have confirmed that NPS affects 
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basal synaptic transmission and plasticity at CA3-CA1 synapses (Ionescu et al., 
2012). Therefore, the next step consisted in characterizing the role of the 
hippocampus in mediating the anxiolytic effects of NPS at the behavioral level by 
local injection of NPS into the ventral CA1 region, a method widely used hitherto for 
characterization of the amygdala in NPS-elicited behavior (Jüngling et al., 2008; 
Fendt et al., 2010). 
3.4.1. Cy3-NPS distribution is restricted to the ventral CA1 region (vCA1) after 
local injection 
In order to ascertain that NPS, after injection into vCA1, will not spread to other brain 
regions and thereby result in hippocampus-independent effects, Cy3-NPS was 
injected into vCA1 and its distribution was subsequently analyzed. Already a small 
amount of Cy3-NPS (0.01 nmol) resulted in intracellular uptake close to the injection 
site (Figure 28).  
 
Figure 28. Cy3-NPS (0.01 nmol) is locally confined to the injection site after injection into 
vCA1. Injection site on sagittal brain section (4x magnification), followed by 20x 
magnification. Nuclear staining: DAPI (blue). Cy3-NPS: red. Long arrows 
indicate injection site. Short arrows indicate cells having taken up Cy3-NPS. All 
images were taken with a confocal microscope. DG: dentate gyrus; vCA1: 
ventral CA1 region; CA3 region. Scale bars 4x: 200 µm; scale bars 20x: 40 µm. 
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Figure 29. Cy3-NPS (0.07 nmol) is locally confined to the injection site after injection into 
vCA1. A Leftmost: Injection site on anatomical plate (Franklin and Paxinos, 
2007). Middle and right: Overlay of DAPI (nuclear staining, blue) and Cy3 (red) 
signals at 4x (left) and 20x (right) magnification. Arrow indicates injections site 
on brain section. B Left: Anatomical plate showing lateral amygdala (LA) and 
basolateral amygdala (BLA) (Franklin and Paxinos, 2007), and (right) overview 
of amygdala in brain section after injection of vCA1 at 4x magnification (overlay: 
DAPI and Cy3 channels; inset: Cy3 channel). All images were taken with a 
confocal microscope. Scale bars 4x: 200 µm; scale bars 20x: 20 µm. 
3.4.2. NPS injection into vCA1 leads to anxiolytic locomotion-independent 
effects 
Having proved that NPS does not spread outside the injection site, the next question 
was whether injection of NPS into vCA1 is sufficient to produce similar anxiolytic 
effects as the already published intra-amygdala (Jüngling et al., 2008) and ICV 
injection (Xu et al., 2004; Jüngling et al., 2008; Leonard et al., 2008; Rizzi et al., 
2008). Since locomotory changes may influence anxiety-related read-out in 
behavioral assays, basal locomotion was examined in the open field and anxiety- and 
locomotion-related parameters in the dark-light test and in the EPM, which have been 
shown to highlight different aspects of anxiety-related behavior (Gonzalez et al., 
1996; van Gaalen and Steckler, 2000; Bailey et al., 2007) (for a complete overview of 
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the experimental schedule please see Figure 30). Injection sites into vCA1 are shown 
in Figure 31A.  
 
Figure 30. Overview of experimental timeline of NPS injection into vCA1. Injection was 
performed at 0 min, and 30 min later, mice underwent the behavioral assays 
open field, dark-light box and EPM in this sequence. 
Intrahippocampal NPS treatment did not affect locomotion in any of the three tests 
(Figure 22B-D). Most important, however, NPS elicited anxiolytic effects in the EPM, 
as shown by a significant increase in the percent time spent on the open arm (t = 
2.227, df = 14, p = 0.0429) (Figure 31D). These anxiolytic effects were locomotion-
independent, since the total number of entries in the closed arm remained 
unchanged (t = 0.2035, df = 14, p = 0.8416) (Figure 31D). These test-specific effects 
coincide well with our previous findings that intranasally applied NPS elicits the 
strongest anxiolytic effects in the EPM (Ionescu et al., 2012). 
Taken together, these results not only confirm our previous report of NPS target 
neurons in the hippocampus (Ionescu et al., 2012), but also show that 
intrahippocampal injection of NPS is sufficient to produce anxiolytic behavioral 
effects.  
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Figure 31. NPS injection into the ventral CA1 region (vCA1) produces anxiolytic, locomotion-
independent effects in the EPM. A Overview of injection sites on anatomical plate 
(Franklin and Paxinos, 2007). B Basal locomotion in open field test (t = 1.928, df = 
14, p = 0.0744). C Anxiety- and locomotion-related parameters in the dark-light 
test (% time in light chamber: t = 0.04641, df = 14, p = 0.9636; % distance in light 
chamber: t = 0.7346, df = 14, p = 0.4747). D Anxiety- and locomotion-related 
parameters in the EPM. Data are shown ± s.e.m. Statistical analysis: two-tailed 
unpaired t-test. * p < 0.05. 
 
3.5. Acute intranasal NPS treatment in high anxiety behavior (HAB) mice, a 
mouse model for pathological anxiety 
Intranasal NPS treatment was shown here to elicit anxiolytic effects in C57BL/6N 
mice. The next step was to examine the therapeutic effects of NPS in a mouse model 
of pathological anxiety. The HAB mice that have been inbred for over 40 generations 
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for pathologically high trait anxiety (Landgraf et al., 2007) (see 1.6.1.) were selected 
for this purpose. NPS was applied intranasally at 14 nmol/animal, the dose that was 
found to have optimal anxiolytic effects in the EPM in C57BL/6N mice (see 3.3.1.). 
The mice were then exposed to the same behavioral testing paradigm as used for 
C57BL/6N mice (open field, dark-light test and EPM) 4 hours after application (see 
Figure 22). 
3.5.1. Behavioral phenotype after intranasal NPS application 
In the open field, NPS had no effects on basal locomotion (t = 0.8610, df = 19, p = 
0.2000) (Figure 32A). In the dark-light test, however, the percent time spent in the 
light chamber was significantly increased (t = 2.316, df = 18, p = 0.0163) and 
moreover, there was also a trend towards decreased latency to the first entry in the 
light chamber, as observed in C57BL/6N mice (t = 1.451, df = 18, p = 0.0820) (Figure 
32B). These results were locomotion-independent, as the percent distance traveled 
in the light chamber remained unchanged between NPS-treated and control animals 
(t = 0.8146, df = 18, p = 0.2130). NPS treatment did not induce any changes in the 
EPM, either in the percent time spent on the open arm (t = 0.6839, df = 18, p = 
0.2514) or in the number of entries into the closed arm (t = 0.07032, df = 18, p = 
0.4724) (Figure 32C). 
In conclusion, NPS treatment can induce anxiolytic effects even in the case of 
pathologically high anxiety, an aspect which had hitherto not been investigated. This 
is evidenced in the case of the HAB mice by locomotion-independent reduction of 
anxiety in the dark-light test. 
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Figure 32.  Behavioral effects of transnasally delivered NPS in HAB mice. HAB mice were 
tested 4 hours after intranasal NPS treatment (14 nmol) in A open field, B dark-
light test and C EPM. n = 10. Statistical analysis: one-sided unpaired t-test. t p < 
0.1; * p < 0.05. All data are shown as mean ± s.e.m. 
 
3.5.2. Regulatory effects of NPS on protein and mRNA expression of proteins 
involved in the glutamatergic system and synaptic plasticity 
Since it has been established previously in this work that NPS has regulatory effects 
on protein expression in C57BL/6N mice, it was interesting to examine this aspect in 
the HAB mice as well. For this purpose, the same candidates that had been 
examined in C57BL/6N mice (GluR1, GluR2, Glt-1 and synapsin isoforms I and II) 
were now investigated at the mRNA level 4 hours after treatment and at the protein 
level 24 hours after treatment in hippocampus and prefrontal cortex. 
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4 hours after treatment, NPS treatment led to significantly decreased mRNA 
expression of GluR1 (t = 2.361, df = 8, p = 0.0459) as well as to a trend towards 
decreased mRNA expression of Glt-1 (t = 2.198, df = 8, p = 0.0591) in the 
hippocampus (Figure 33A). The last finding corresponds to the observations in the 
hippocampus of NPS-treated C57BL/6N mice. In the prefrontal cortex, NPS had no 
effects on mRNA expression of the examined candidates (Figure 33B). 
 
Figure 33. Effects of transnasally delivered NPS (14 nmol) 4 hours after application on 
mRNA levels in hippocampus (Hc) and prefrontal cortex (Pfc) of HAB mice. A 
Real-time PCR analysis of Hc lysate from HAB mice 4 hours after intranasal 
NPS treatment. GluR2: t = 1.540, df = 8, p = 0.1620; Synapsin I: t = 1.123, df = 
8, p = 0.2940; Synapsin II: t = 1.339, df = 5, p = 0.2383. B Real-time PCR 
analysis of Pfc lysate from HAB mice 4 hours after intranasal NPS treatment. 
GluR1: t = 0.7371, df = 7, p = 0.4850; GluR2: t = 0.7957, df = 8, p = 0.4492; Glt-
1: t = 0.2440, df = 7, p = 0.8143; Synapsin I: t = 0.8174, df = 8, p = 0.4373; 
Synapsin II: t = 0.4126, df = 8, p = 0.6907. HAB: n = 5 for each group. Statistical 
analysis: two-tailed unpaired t-test. t p < 0.1; * p < 0.05. All data are shown as 
mean ± s.e.m. 
24 hours after treatment, there were no differences in protein expression levels of the 
examined candidates in the hippocampus (Figure 34A). However, in the prefrontal 
cortex, NPS-treated HAB mice displayed a trend towards increased protein 
expression of GluR1 (t = 2.228, df = 10, p = 0.0500), as well as significantly 
increased GluR2 protein expression (t = 2.832, df = 10, p = 0.0178) (Figure 34B). 
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Figure 34. Effects of transnasally delivered NPS (14 nmol) 24 hours after application on 
protein levels in hippocampus (Hc) and prefrontal cortex (Pfc) of HAB mice. A 
Immunoblot analysis of Hc lysate from HAB mice 24 hours after intranasal NPS 
treatment. GluR1: t = 0.2502, df = 9, p = 0.8081; GluR2: t = 0.1124, df = 10, p = 
0.9127; Glt-1: t = 1.582, df = 10, p = 0.1447; Synapsin Ia-b/IIa: t = 1.197, df = 9, 
p = 0.2619. B Immunoblot analysis of Pfc lysate from HAB mice 24 hours after 
intranasal NPS treatment. Glt-1: t = 0.8817, df = 9, p = 0.4009; Synapsin Ia-
b/IIa: t = 0.9739, df = 10, p = 0.3531. Internal expression control: GAPDH (35 
kDa in immunoblot excerpts). Blot excerpts show three representative adjacent 
bands of each group. The immunoblot data represent cumulated data from at 
least three independent experiments. HAB: n = 5 for each group. Statistical 
analysis: two-tailed unpaired t-test. t p < 0.1; * p < 0.05. All data are shown as 
mean ± s.e.m. 
In conclusion, NPS exerts regulatory effects on mRNA and protein expression of 
candidates involved in the glutamatergic circuit also in a mouse model of pathological 
anxiety. These regulatory effects of intranasally applied NPS in HAB mice overlap in 
part with those observed in C57BL/6N mice, i.e. in the case of Glt-1 mRNA 
expression in the hippocampus and GluR1 protein expression in the prefrontal 
cortex.  
3.6. Acute intranasal NPS treatment in a mouse model of PTSD 
In order to test whether NPS treatment can improve PTSD-related symptoms, 
shocked mice were treated intranasally with either NPS or vehicle daily on three 
consecutive days starting at day 28 post-shock, a time-point at which a full-blown 
PTSD-like pathology has been described in this mouse model (Siegmund and 
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Wotjak, 2007). Behavioral and molecular analyses were then performed to examine 
the influence of NPS on the phenotype of these mice. 
3.6.1. Behavioral results 
The behavioral phenotype of the mice was evaluated in three tests performed on 
three consecutive days (for an overview of the experimental schedule see Figure 35).  
 
Figure 35.  Overview of the experimental timeline in intranasal NPS application in a mouse 
model of PTSD. A At day 0 (d0), mice received the electric shock. B At day 28 
(d28), mice were treated intranasally with either vehicle or NPS and 2 hours 
later tested for conditioned fear in the shock context. C At day 29 (d29), mice 
were treated with either vehicle or NPS and 2 hours later tested for social 
interaction. D At day 30 (d30), mice were treated with either vehicle or NPS and 
2 hours later tested for their acoustic startle response. E At day 31 (d31), mice 
were sacrificed for brain removal, from which protein and mRNA were 
subsequently isolated. 
 
 
Figure 36.  Behavioral effects of NPS treatment in the mouse model of PTSD. A Response 
to reexposure to conditioning context (CS +) measured in % freezing. B 
Measure of social interaction. C Intensity of acoustic startle response (ASR) to a 
tone of increasing sound level. The data represents mean peak startle 
amplitude in response to 30 stimuli of each intensity value. 
The parameters measured were: percent freezing in the shock context (CS +), 
percent social interaction and intensity of acoustic startle response (ASR) depending 
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on noise intensity. No differences were observed in these parameters between NPS-
treated and vehicle-treated shocked mice (Figure 36). 
3.6.2. Analyses of mRNA and protein expression in hippocampus and 
prefrontal cortex in the PTSD mouse model 
The molecular effects of NPS treatment were examined in this mouse model in 
addition to the behavioral read-out of NPS-treated shocked mice, in order to fully 
characterize the potential therapeutic effects of this substance. Therefore, in addition 
to behavioral testing, changes in mRNA and protein levels of selected candidates 
that had been found to be regulated by NPS treatment in non-shocked C57BL/6N 
and HAB mice (see 3.3.2. and 3.5.2.) were examined in the hippocampus and 
prefrontal cortex, two brain regions that have been described as affected in PTSD 
(Shin et al., 2004, 2006; Golub et al., 2011). Again, these candidates were GluR1, 
GluR2, Glt-1, and synapsin (isoforms I and II). 
In the hippocampus of shocked mice, NPS treatment led to increased synapsin I (t = 
2.408, df = 7, p = 0.0469) and II (t = 2.525, df = 8, p = 0.0355) mRNA levels, as well 
as to an upward trend in synapsin Ia-b/IIa protein expression (t = 2.140, df = 7, p = 
0.0696) compared to vehicle-treated controls 24 hours after the last application 
(Figure 37D). 
In addition, a trend towards increased expression of GluR1 (t = 2.049, df = 8, p = 
0.0746) and GluR2 (t = 2.016, df = 7, p = 0.0836) mRNA was observed (Figure 37A). 
On the protein level, these changes did not materialize in the case of GluR1, 
whereas GluR2 protein expression decreased significantly (t = 4.341, df = 7, p = 
0.034) (Figure 37B). On the other hand, Glt-1 mRNA and protein expression 
remained unaffected (Figure 37C). 
In the prefrontal cortex, NPS treatment resulted in an upward trend in GluR2 mRNA 
expression (t = 2.2028, df = 8, p = 0.0770), while GluR2 protein expression remained 
unchanged (t = 1.591, df = 8, p = 0.1504) (Figure 38A). There were no other changes 
in mRNA or protein expression of any of the observed candidates (Figure 38B, C and 
D). 
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Figure 37.  Effects of NPS treatment in the hippocampus on mRNA and protein expression of proteins 
involved in the glutamatergic circuit and in synaptic plasticity in shocked mice. A GluR1 
mRNA and protein (t = 0.2528, df = 8, p = 0.8068) expression. B GluR2 mRNA and 
protein expression. C Glt-1 mRNA (t = 1.219, df = 8, p = 0.2575) and protein (t = 0.7859, 
df = 8, p = 0.4546) expression. D Synapsin I and II mRNA and synapsin Ia-b/IIa protein 
expression expression. Internal expression control: GAPDH (35 kDa in immunoblot 
excerpts). Blot excerpts show three representative adjacent bands of each group. The 
immunoblot data represent cumulated data from at least three independent experiments. 
n = 5. Statistical analysis: two-tailed unpaired t-test. t p < 0.1; * p < 0.05. All data are 
shown as mean ± s.e.m. 
 
Figure 38.   Effects of NPS treatment in the prefrontal cortex on mRNA and protein expression of 
proteins involved in the glutamatergic circuit and in synaptic plasticity in shocked mice. 
A GluR2 mRNA and protein (t = 1.591, df = 8, p = 0.1504) expression. B GluR1 mRNA 
(t = 1.719, df = 8, p = 0.1239) and protein (t = 1.591, df = 8, p = 0.5467) expression. C 
Glt-1 mRNA (t = 0.8482, df = 8, p = 0.4210) and protein (t = 0.7889, df = 8, p = 0.4529) 
expression. D Synapsin I and II mRNA expression (t = 0.2337, df = 7, p = 0.8219) and 
synapsin Ia-b/IIa protein expression (t = 0.6485, df = 8, p = 0.5348). Internal expression 
control: GAPDH (35 kDa in immunoblot excerpts). Blot excerpts show three 
representative adjacent bands of each group. The immunoblot data represent 
cumulated data from at least three independent experiments. n = 5. Statistical analysis: 
two-tailed unpaired t-test. t p < 0.1. All data are shown as mean ± s.e.m. 
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3.6.3. Corticosterone plasma levels 
Given that NPS has been shown to influence the HPA axis (Smith et al., 2006), which 
is known to be affected in PTSD (Ehlert et al., 2001; Shea et al., 2005; de Kloet et al., 
2006), corticosterone levels were investigated by corticosterone ELISA in plasma 
samples of shocked mice. Acute NPS treatment at day 28 after shock led to a trend 
towards increased plasma corticosterone levels compared to vehicle treatment (t = 
1.802, df = 14, p = 0.0932) (Figure 39B).  
In conclusion, NPS treatment in the PTSD mouse model did not affect the behavioral 
phenotype. At the molecular level on the other hand, NPS regulated expression 
levels of examined candidates both on mRNA and on protein level and, most 
importantly, led to an increase in synapsin levels that had also been observed in non-
shocked C57BL/6N mice (see 3.3.2.). Moreover, NPS increased circulating 
corticosterone plasma levels up to 24 hours after treatment. 
 
Figure 39.   Corticosterone levels in plasma obtained from trunk blood of shocked mice after 
NPS treatment. A Fitted curve in a semi-log plot showing known corticosterone 
concentrations in ng/ml at the power of 10 from the calibrator samples C0-C5 
and the corresponding absorbtion values. B Graph showing mean 
corticosterone concentrations (extrapolated from fitted curve) of the two groups. 
Statistical analysis: two-tailed unpaired t-test. t p < 0.1. All data are shown as 
mean ± s.e.m. 
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4. Discussion 
4.1. Anxiolytic effects of intranasally applied NPS in C57BL/6N and HAB mice 
The main focus of this study was the characterization of NPS-elicited anxiolytic 
effects in view of the potential of NPS as a novel therapeutic for anxiety disorders, 
including PTSD. NPS represents a prime candidate for this purpose, since, although 
it has been reported to have reward-like effects (Cao et al., 2011), it does not act via 
the GABAA receptor like benzodiazepines and therefore will most likely not have their 
undesirable side-effects, especially as regards sedation, a common secondary action 
of benzodiazepine treatment (Cloos and Ferreira, 2009).  
Most important for the implementation of an NPS-based therapy in patients was 
establishing a non-invasive application procedure appropriate for use in humans, as 
opposed to the ICV administration that was hitherto used in rodents. The results 
presented here show for the first time that intranasally applied NPS can successfully 
target the mouse brain. Although work done by others has already revealed that 
intranasally applied substances, among them neuropeptides, can target the CNS 
(Born et al., 2002; Dufes et al., 2003; Thorne et al., 2004, 2008; Dhuria et al., 2009), 
this was until now not proven in the case of NPS. Testing the feasibility of intranasal 
NPS delivery was crucial, since only the molecular structure of a substance is 
generally not sufficient to predict whether and to what extent the substance of 
interest will reach the brain after intranasal delivery (Ozsoy et al., 2009; Dhuria et al., 
2010). In addition, even if the substance is able to bypass the nose-brain barrier and 
reach the brain, it is still a considerable challenge to identify the correct dosis for 
eliciting the desired therapeutic effects, since the nasal bioavailability of hydrophilic 
peptides and proteins is usually below 1 % (Ozsoy et al., 2009), in part as a 
consequence of the neuropeptide-degrading enzymes of the nasal mucosa (Ohkubo 
et al., 1994).  
It is therefore remarkable that here, NPS could not only be tracked within the murine 
brain after intranasal application, but also induced locomotion-independent anxiolytic 
effects in mice. The data on successful transnasal delivery of NPS to alert mice 
presented here strongly encourage the development of NPS-based anxiolytics by 
providing the basis for intranasal NPS administration in patients.  
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The behavioral results obtained in C57BL/6N mice treated intranasally with NPS are 
very similar to the ones described previously by others after ICV injection of NPS 
(Jüngling et al., 2008; Leonard et al., 2008). The effects of NPS on both anxiety and 
locomotion were examined in two different standardized behavioral assays: the dark-
light test and the EPM. This was done to improve the characterization of the NPS-
induced behavioral phenotype, since both tests have been shown to cover different 
facets of anxiety (van Gaalen and Steckler, 2000; Bailey et al., 2007). The first test 
performed was the open field, which may be considered a fairly stressful experience 
for the animals. While it cannot be excluded with absolute certainty that the sequence 
of the tests might affect the behavioral readout, it is unlikely to assume that the 
control and treatment group were affected differently by this experience, as they did 
not show any difference in locomotion in the open field. The only possible way to 
circumvent the potential inter-test effects would have been to perform the assays on 
different days, so as to allow sufficient time for the influence of the single tests to 
disappear. However, this would have led to the additional difficulty of repeated NPS 
treatment, which would also have biased the results due to potential effects of 
chronic versus acute treatment. Although the behavioral effects of intranasal NPS 
treatment become apparent at a later time-point than described for ICV injection (4 
hours instead of 30 min), this difference is most likely a consequence of dissimilar 
pharmacokinetics and targeting efficiencies of intranasally versus ICV-administered 
drugs (Thorne et al., 1995, 2008; Shi et al., 2010). This assumption is supported by 
the fact that at 30 min after intranasal application, a much weaker signal was 
observed than after ICV application. Therefore, although NPS reaches the brain 
rapidly after intranasal administration, additional time may be necessary for the 
substance to reach its brain target cells in the full concentration required to produce 
behavioral effects. In combination with the results describing NPS-induced changes 
in expression levels of candidate proteins up to 24 hours after treatment, future 
studies characterizing an even more extended timeline of NPS effects will be helpful. 
As shown here for the first time, NPS treatment also exerts anxiolytic effects in HAB 
mice, a mouse model of pathological anxiety. These effects become apparent in HAB 
mice only in the dark-light test and not in the EPM as well, where reduced anxiety 
was also apparent in C57BL/6N mice. This may be the consequence of different 
neurobiological mechanisms underlying the general condition of trait anxiety 
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represented by the HAB mice versus the temporary condition of state anxiety 
(Krömer et al., 2005; Bunck et al., 2009). Moreover, the HAB mice are selected 
according to their behavior on the EPM (Krömer et al., 2005; Hambsch et al., 2010), 
which means that they have already been exposed to this test once. This prior 
exposure may additionally sensitize them towards this test and may contribute to 
making their behavior particularly resistant against pharmacologically induced 
changes in this test, as shown by others in the case of benzodiazepine treatment 
(Gonzalez and File, 1997). NPS-elicited anxiolytic effects in HAB mice are highly 
promising, since they show that NPS may mitigate the phenotypic consequences of a 
genetic predisposition to high anxiety-related behavior. 
These results represent a starting point for future studies exploring the precise 
pharmacokinetics of intranasally applied NPS. Additionally, this application method 
will most likely facilitate animal experiments studying NPS effects, since it 
considerably reduces the stress the animals are exposed to during treatment as 
compared to the surgery-dependent intracerebral injection used in previous studies 
(Xu et al., 2004; Jüngling et al., 2008; Leonard et al., 2008; Fendt et al., 2010). 
4.2. Identification of target brain regions and target neurons of NPS by NPSR-
mediated internalization of Cy3-NPS 
Here, the brain target regions and target neurons of NPS were identified with a high 
specificity by application of Cy3-NPS. Fluorescently labeled neuropeptides have 
been previously used by others both to study specific receptor-ligand interactions and 
to identify target cells both in vitro (Bunnett et al., 1995; Grady et al., 1995) and in 
vivo (Hubbard et al., 2009). The work at hand is however the first one to combine in 
vitro use of fluorophore-coupled ligands with intracerebral tracking after intranasal 
application in vivo.  
The cell culture results presented here prove that intracellular Cy3-NPS uptake is 
receptor-mediated and takes place only in those cells that express NPSR at the 
membrane. This GPCR-dependent internalization process occurs upon highly 
specific interaction between the ligand and its respective receptor and represents a 
cellular desensitization mechanism described also for other neuropeptide receptors 
(Grady et al., 1995; Hökfelt et al., 2003; Reyes et al., 2006). However, in the case of 
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NPS, this phenomenon had not yet been explicitly demonstrated. The only work in 
this direction so far had been performed using vasopressin stimulation of a chimeric 
construct of vasopressin and NPS receptor elements (Gupte et al., 2004). Therefore, 
the physiological significance of those findings was limited. The results obtained in 
the course of the study presented here constitute the first evidence for agonist-
induced internalization of wild-type murine NPSR. Although it is known that some 
neuropeptides can directly cross the plasma membrane and exert effects in a 
receptor-independent manner (Saban et al., 2002; Prochiantz and Joliot, 2003; 
Marinova et al., 2005), this does not seem to be the case here, since the only uptake 
observed occurs in cells expressing the tagged NPSR-construct. Moreover, Cy3-NPS 
is highly apparent at the membrane immediately following stimulation, in contrast to 
cell-penetrating neuropeptides, such as dynorphin, which are located mainly in the 
cytoplasm (Marinova et al., 2005). Finally, the Cy3-NPS signal colocalized 
exclusively with the signal of the receptor-specific immunostaining (Figures 10, 11). 
This is quite compelling evidence for the fact that NPS internalization is dependent 
upon expression of active NPSR at the cell membrane. 
These cell culture results permit the assumption that the internalization of Cy3-NPS 
in single cells of various brain regions upon ICV and intranasal administration in vivo 
also represents a receptor-mediated process. Besides proving the feasibility of 
targeting the brain by intranasal administration, this approach led to another major 
finding, namely the identification of the hitherto unknown NPS target brain regions 
and target neurons. The validity of these results is supported by publications which 
link some of the brain regions identified here with NPS-mediated effects. This is the 
case for the basolateral and lateral amygdaloid nuclei; here, not only were anxiolytic 
effects described upon local NPS injection, but also NPSR mRNA expression was 
found in the mouse (Jüngling et al., 2008). This also holds true for the hypothalamus 
(Smith et al., 2006; Fedeli et al., 2009; Yoshida et al., 2010). Moreover, the target 
brain regions of NPS were identified here by two different application methods, 
intranasal and ICV administration. Since the distribution pathways of substances vary 
according to the delivery approach used, the overlap between NPS target brain 
regions identified by these two methods very much strengthens the conclusion that 
these brain regions are indeed the physiological targets of NPS (see Table 11). 
These results partly contradict previous NPSR expression studies, as for instance in 
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the case of the hippocampus, where Cy3-NPS uptake is observed in the work at 
hand but where no NPSR mRNA seems to be expressed in the rat brain (Xu et al., 
2007). This is most likely the consequence of differential NPSR expression patterns 
between rat and mouse, a fact that has already been proven in the case of the 
basolateral amygdala, where abundant NPSR mRNA expression was detected only 
in the mouse (Jüngling et al., 2008). Additionally, control experiments in which Cy3-
NPS uptake was blocked using NPSR-specific antagonists strongly indicate that this 
uptake is NPSR-dependent. Furthermore, the internalization pattern of Cy3-NPS in 
brain neurons after intranasal administration coincides with that observed in cell 
culture upon internalization of the receptor-ligand complex (see Figures 10, 11, 19). 
Finally, it is known that, in NPSR-KO mice, NPS treatment no longer exerts its 
described effects (Zhu et al., 2010), thus proving that NPSR is the only mediator of 
NPS actions. The ultimate confirmation, which could result from an immunostaining 
against NPSR and investigation of the signal compared to the Cy3-NPS signal, 
represents an important future experimental approach.  
The novelty of these findings consists in the identification of the physiological target 
brain regions and target cells of NPS. In contrast to current NPSR expression studies 
using ISH and immunostaining, the NPS target cells identified here are the ones 
where NPSR is expressed not only on mRNA level or within the cytoplasm, but is 
actually present at the membrane and can therefore bind to its ligand and most likely 
as a consequence activate the signaling cascade. Furthermore, using a fluorescent 
conjugate of NPS it was possible, for the first time, to track intranasally administered 
substances at the single cell level. This much improves the anatomical resolution of 
intracerebral distribution patterns hitherto available with radioactively labeled ligands 
(Thorne et al., 2004, 2008). 
4.3. The hippocampus: A novel player in NPS-mediated anxiolytic effects 
Most important, both intranasal and ICV administration of Cy3-NPS led to 
identification of the hippocampus as a novel NPS target region. NPSR mRNA and 
protein expression studies contain contradictory results with respect to the 
hippocampus. In the rat, no NPSR mRNA expression was detected in the CA1, CA2 
and CA3 regions and in the dentate gyrus by ISH (Xu et al., 2007); immunostaining 
against NPSR on the other hand revealed sparse immunoreactivity in these same 
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hippocampal regions (Leonard and Ring, 2011). In the study at hand, however, 
abundant Cy3-NPS uptake was observed in the ventral as well as throughout the 
dorsal hippocampus, spanning all CA regions and the dentate gyrus.  
As far as NPS effects in the hippocampus are concerned, there was until now no 
direct link between NPS treatment and modulation of hippocampal function with 
regard to NPS-elicited anxiolytic effects. The only observations so far relating NPS to 
the hippocampus presented only an indirect link between NPS actions and the 
hippocampal region by showing that NPS treatment increases phosphorylation of 
cAMP-response element binding protein (CREB) in the hippocampus, which the 
authors of the study hypothesized to play a role in reversing impairment of spatial 
memory after rapid eye movement (REM) sleep deprivation (Zhao et al., 2010). 
The work at hand demonstrates that NPS injection specifically into the ventral 
hippocampus is sufficient to elicit anxiolytic effects similar to those observed after 
intra-amygdala and ICV injection (Xu et al., 2004; Jüngling et al., 2008). As shown in 
the present study, these behavioral changes are initiated only within the ventral CA1 
region (the site of injection), since it was shown here additionally that Cy3-NPS 
distribution upon intrahippocampal injection remains locally restricted and does not 
reach the amygdala. Moreover, electrophysiological data obtained in parallel to this 
work show modulation of basal synaptic transmission, of transmitter release 
probability and of short- and long-term plasticity in the ventral hippocampus 2 hours 
after slice incubation with NPS (Ionescu et al., 2012). Interestingly, these 
electrophysiological results could be replicated in slices from the ventral 
hippocampus prepared 4 hours after intranasal NPS treatment in C57BL/6N mice 
(Dine*, Ionescu* et al., in preparation). This strongly supports the conclusion that the 
observed NPS-elicited activity changes are of physiological relevance and pertain to 
the endogenous brain network activity.  
Here is shown that NPS treatment upregulates hippocampal synapsin Ia-b/IIa protein 
expression in mice 24 hours after application. This observation strengthens the 
electrophysiologically identified increase in neurotransmitter release probability after 
NPS treatment. As synapsin has been shown to be involved in modulation of 
neurotransmitter release by regulation of synaptic vesicles availability (Humeau et al., 
2001; Baldelli et al., 2007; Cesca et al., 2010), increased synapsin expression may 
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mirror an increased number of synaptic vesicles at presynaptic terminals. 
Furthermore, the protein data obtained 24 hours after NPS treatment suggest that 
the effects observed 2 hours after slice incubation with NPS may continue in the 
long-term. More detailed investigation of NPS effects over an extended period of 
time, as well as high-resolution microscopy, for instance electron microscopy, to 
accurately quantify potential changes in the synaptic vesicle pools will be needed for 
verifying this hypothesis. 
The anxiolytic effects elicited by NPS injection into the ventral CA1 region and the 
synapsin upregulation upon intranasal NPS treatment together with the 
electrophysiological data showing NPS-induced modulation of hippocampal activity 
strongly point towards the hippocampus as a novel major player in NPS-mediated 
anxiolytic effects (Figure 40). This is especially important since hitherto, the main 
focus has been on the amygdala as the key mediator of the anxiolytic NPS effects 
(Meis et al.; Jüngling et al., 2008; Fendt et al., 2010; Pape et al., 2010). The findings 
presented here do not contradict this model; rather, they complement it. The ventral 
hippocampus and especially the ventral CA1 region are associated with the 
amygdaloid nuclei by extensive bidirectional connections (Fanselow and Dong, 2010) 
(green arrows in Figure 40). Moreover, during the past decade, the role of the ventral 
hippocampus in regulating anxiety and fear formation and expression has emerged 
more and more clearly (Kjelstrup et al., 2002; Bannerman et al., 2004; McHugh et al., 
2004). Therefore, the data presented here strongly suggest that upon NPS 
stimulation, the ventral hippocampus modulates the activity of amygdaloid nuclei to 
decrease anxiety in addition to the direct effects of NPS in the amygdala. 
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Figure 40.  Effects of NPS in amygdaloid structures (Pape et al., 2010) and in the ventral 
CA1 region (Franklin and Paxinos, 2007). Red arrows show identified targets of 
NPS. Green arrows show input connections from the lateral amygdala to the 
ventral CA1 region and output connections from the ventral CA1 region to the 
central amygdala. LA: lateral amygdala; BLA: basolateral amygdala; EPC: 
endopiriform cortex; CeA: central amygdala; vCA1: ventral CA1 region; mpara: 
medial paracapsular interneurons; lpara: lateral paracapsular interneurons. 
 
4.4. NPS and the glutamatergic system in C57BL/6N and HAB mice 
In addition to hippocampal regulation of synapsin expression, NPS treatment also led 
to regulation of protein and mRNA expression of proteins associated with the 
glutamatergic system. 
Although NPS actions have been previously linked to the glutamatergic system (Han 
et al., 2009; Okamura et al., 2010, 2011), there was hitherto no data available on 
regulatory effects of NPS in vivo. This work provides evidence that NPS treatment 
differentially regulates cerebral expression of GluR1, GluR2 and Glt-1 on both mRNA 
and protein level in C57BL/6N mice as well as in HAB mice in a region- and strain-
dependent manner (see Figures 25-27, 33, 34). This is especially relevant since the 
glutamatergic system is known to be affected in psychiatric disorders like PTSD, 
where toxically increased glutamate release is thought to play a role in hippocampal 
shrinkage, as well as in consolidation of traumatic memories (Ravindran and Stein, 
2009; Rossi et al., 2009). 
GluR1 protein expression is increased in the prefrontal cortex of NPS-treated 
C57BL/6N mice, whereas GluR2 expression remains unaffected. This process might 
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result in an increased GluR1:GluR2 ratio, which reflects an enhancement of AMPA 
receptor function (Isaac et al., 2007). As acute potentiation of AMPA receptors in the 
prefrontal cortex has been shown to facilitate fear extinction (Zushida et al., 2007), 
specific upregulation of GluR1 by NPS treatment might provide a hint towards long-
term NPS-mediated fear extinction following chronic NPS treatment. This speculation 
is supported by results showing that NPS treatment can facilitate fear extinction upon 
intra-amygdala injection (Jüngling et al., 2008). To further test this hypothesis, 
investigation of GluR1 and GluR2 expression specifically at the membrane as well as 
an AMPA binding assay will have to be performed in order to check whether the 
observed increase in total-cell GluR1 protein expression is also mirrored on a 
functional level. 
In HAB mice, in contrast to C57BL/6N mice, NPS treatment upregulates protein 
expression of both GluR1 and GluR2. This might be the consequence of a different 
baseline activity of the glutamatergic system in the two strains, especially since the 
HAB mice represent a model of pathologically enhanced trait anxiety. In anxiety 
disorders and PTSD, hyperactivity of the glutamate system might lead to chronic 
potentiation of AMPA receptors and thereby to glutamate excitotoxicity (Tanaka et 
al., 2000). It has been noted that affected neurons express a reduced amount of 
GluR2 subunits. Therefore, it can be speculated that NPS actions under pathological 
conditions are capable of restoring homeostasis in the glutamate system. 
In C57BL/6N mice, NPS also upregulates cerebral Glt-1 mRNA and protein 
expression in the prefrontal cortex in addition to the expression of AMPA receptor 
subunits. Since glutamate excitotoxicity has been reported in PTSD (Ravindran and 
Stein, 2009; Rossi et al., 2009), increase in Glt-1 levels may represent a possible 
damage-limiting mechanism of NPS actions. Moreover, since Glt-1 is expressed 
exclusively by astrocytes (Huang and Bergles, 2004), these data show that NPS, 
although it targets only neurons, can ultimately impact the entire cellular brain 
network. 
The changes in protein expression described here represent valuable starting points 
for further investigation of the mechanisms underlying complex NPS-mediated 
effects, especially in the context of the behavioral and electrophysiology results. 
These changes in protein expression only become apparent 24 hours after treatment. 
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However, regulation of membrane transport and insertion mechanisms may occur 
already at an earlier time point and lead to the electrophysiological and behavioral 
effects described at 2 and 4 hours after NPS administration, respectively. Further 
studies on protein levels of cellular subfractions and on protein dynamics are needed 
to clarify this aspect. The fact that the cerebral expression of the examined 
candidates is differentially modulated at protein and mRNA levels, as well as the fact 
that these processes seem to be time-, region- and strain-dependent, suggest that 
NPS-mediated regulation of protein expression taps into a variety of 
posttranscriptional and posttranslational mechanisms to exert its effects.  
Taken together, these expression analyses provide new insights into potential 
regulatory mechanisms of NPS in vivo, which have hitherto been explored in vitro 
and at the RNA level only (Vendelin et al., 2006). 
4.5. Effects of NPS treatment on cerebral protein expression in a mouse model 
of PTSD 
Regulatory effects of NPS on protein expression were also described in a mouse 
model of PTSD (Siegmund and Wotjak, 2007). Previous screening of protein 
expression in this mouse model revealed the synapsin isoforms I and II to be 
downregulated in the hippocampus at day 28 post-shock (Herrmann et al., 
submitted). Upon intranasal NPS treatment at day 28, treated mice displayed 
increased synapsin I and II mRNA expression in the hippocampus compared to 
vehicle-treated controls, as well as a trend towards increased synapsin Ia-b/IIa 
protein expression. This finding is most interesting, since it shows that NPS treatment 
has the potential to reverse molecular changes that can be attributed to the PTSD 
pathology.  
Moreover, 24 hours after application, NPS treatment trendwise increased 
corticosterone levels in plasma of treated mice as compared to vehicle-treated 
controls. This observation confirms findings that show stimulatory effects of NPS on 
the HPA axis and increased plasma corticosterone 10 to 40 min after NPS ICV 
injection (Smith et al., 2006). It adds to the previous data by showing that NPS 
effects on blood corticosterone levels are robust enough to last up to 24 hours after 
treatment. Additionally, it provides valuable support in favor of the applicability of 
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NPS as an alternative treatment for PTSD, since in PTSD patients, cortisol plasma 
levels have been found to be decreased (Yehuda et al., 1995; Gill et al., 2008; 
Vythilingam et al., 2010). Upon successful treatment cortisol levels increased in 
responders (Olff et al., 2007). Therefore, these results may point towards an incipient 
success of NPS therapy that might, in time, attenuate at least part of the PTSD 
symptoms. Finally, elevated corticosterone levels after NPS treatment very nicely 
relate to NPS-induced upregulation of hippocampal synapsin expression, since it has 
been shown in cell culture of hippocampal neurons that corticosterone stimulation 
increases synapsin Ia-b expression on the protein level (Revest et al., 2010). 
Moreover, corticosterone has been shown to contribute to synaptic plasticity by 
regulating AMPA receptor trafficking differentially via the glucocorticoid receptor (GR) 
and the mineralocorticoid receptor (MR) (Avital et al., 2006; Krugers et al., 2010). 
Indeed, NPS treatment also evokes changes in expression of AMPA receptor 
subunits GluR1 and GluR2, as described here. 
NPS treatment in the PTSD mouse model elicited no behavioral phenotype. This may 
however be due to the fact that at day 28, the mice already exhibit a full-blown PTSD 
phenotype (Siegmund and Wotjak, 2007) which may be difficult to alleviate by acute 
treatment only. Chronic treatment would have to be attempted at this time-point in 
order to better characterize the curative effects of NPS in the case of PTSD. 
However, the results presented here show that this mouse model could be 
appropriate to study the therapeutic and potential curative effects of NPS on PTSD 
symptoms. Traumatized mice treated with NPS respond to treatment as far as 
corticosterone plasma levels are concerned and they additionally show restoration in 
levels of synapsin, newly identified as a potential biomarker of PTSD (Herrmann et 
al., submitted).  
4.6. Summary 
To sum up, the work presented here establishes a non-invasive procedure for NPS 
administration in mice whereby anxiolytic and HPA axis-regulating effects of NPS are 
preserved, and that may be implemented in patients. Intranasal application of Cy3-
NPS allowed visualization of NPS target cells at a single-cell resolution, thus 
establishing for the first time the use of fluorophore-coupled ligands for substance 
tracking after intranasal application. By this technique, the hippocampus was 
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identified as a novel target brain region of NPS which contributes to mediating its 
anxiolytic effects. Together with results on the regulatory effects of NPS on protein 
and mRNA expression in various brain regions associated with anxiety, these 
findings give new insights into the molecular basis of NPS-elicited effects. Finally, 
therapeutic actions of NPS are shown here for the first time in a high anxiety mouse 
model, the HAB mice, and trauma-counteracting effects of NPS treatment on 
hippocampal expression of synaptic proteins are described here in a mouse model of 
PTSD. This study therefore provides a solid basis for developing an NPS-based 
therapy for patients suffering from anxiety disorders like PD and PTSD.  
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5. Supplementary Material 
 
Supplementary Table 1. List of devices used in this work. 
 
 
Device Firm 
Bio-Rad DNA Subcell system (agarose 
gel electrophoresis) Bio-Rad, Munich, Germany 
Cell culture incubator Heraeus 240i Thermo Scientific, Waltham, MA, USA 
Confocal microscope Olympus IX81 Olympus Soft Imaging Systems GmbH, Münster, Germany 
Cryostat Microm HM 500 OM Thermo Scientific, Walldorf, Germany 
Dynatech MR5000 plate reader Dynatech Laboratories, Denkendorf, Germany 
Epifluorescence microscope Olympus 
BX61 
Olympus Soft Imaging Systems GmbH, 
Münster, Germany 
Kodak M35 X-OMAT Processor Carestream Health Inc, Rochester, NY, USA 
LightCycler®2.0 Roche Diagnostics, Mannheim, Germany 
Mini-Protean Electrophoresis System 
(SDS-PAGE) Bio-Rad, Munich, Germany 
Nanophotometer Implen, Munich, Germany 
PCR thermocycler TProfessional Biometra, Göttingen, Germany 
Plate centrifuge 5804 R Eppendorf, Hamburg, Germany 
Protean GelDoc 2000 system (agarose 
gel analysis) Bio-Rad, Munich, Germany 
Shaker Gyro-Rocker SSL3 Stuart, Staffordshire, UK 
Sonifier Cell Disruptor B15 Branson, USA 
Stereotact TSE Systems, Bad Homburg, Germany 
Table centrifuge 5415 R Eppendorf, Hamburg, Germany 
Turrax homogenizer VDI12 VWR, Darmstadt, Germany 
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Supplementary Table 2. List of materials used in this work. 
 
 
 
Material Firm 
0.2 ml PCR tubes Eppendorf, Hamburg, Germany 
1.5 ml tubes Eppendorf, Hamburg, Germany 
10 µl Hamilton syringe Hamilton Bonaduz AG, Bonaduz, Switzerland 
2 ml tubes Eppendorf, Hamburg, Germany 
23 gage guide cannulas Josef Peske GmbH & Co. KG, Aindling-Arnhofen, Germany 
30 gage injection cannulas VWR, Darmstadt, Germany 
Cell culture vessels (10 cm 
dishes, 6/24/96-well plates) 
Josef Peske GmbH & Co. KG, Aindling-
Arnhofen, Germany 
Cover slips 12 mm  Marienfeld GmbH & Co. KG, Lauda-Königshofen 
Dual-Cement Basis + 
Katalysator Pluradent AG & Co. KG, Munich, Germany 
EDTA 1.5 ml tubes for blood Josef Peske GmbH & Co. KG, Aindling-Arnhofen, Germany 
FujiFilm X-Ray 18x24 100NF Röntgen Bender GmbH & Co. KG, Baden-Baden, Germany 
Gloves SemperGuard 
latex/nitrile powder-free 
Semperit Technische Produkte, Vienna, 
Austria 
LightCycler capillaries (20 µl) Roche Diagnostics, Mannheim, Germany 
Netwells for immunostainings VWR, Darmstadt, Germany 
Neubauer Counting Chamber 
improved Carl Roth GmbH + Co., Karlsruhe, Germany 
Nitrocellulose membrane Carl Roth GmbH + Co., Karlsruhe, Germany 
Parafilm Josef Peske GmbH & Co. KG, Aindling-Arnhofen, Germany 
Research pipettes Eppendorf, Hamburg, Germany 
RNase/DNase-free 0.5 ml tubes Eppendorf, Hamburg, Germany 
RNase-free 2 ml tubes Eppendorf, Hamburg, Germany 
Screws DIN84 1.0x2 Paul Korth GmbH, Lüdenscheid, Germany 
Slides Superfrost® Plus Thermo Scientific, Waltham, MA, USA 
Surgical instruments TSE Systems, Bad Homburg, Germany 
Tygon tube VWR, Darmstadt, Germany 
 
 
 
 
 
5. Supplementary material 
 
 
90
 
 
Supplementary Table 3. List of substances used in this work (sorted alphabetically). 
 
 
 
 
Substance Firm 
(R)-SHA 68 Generous gift from A. Sailer, Novartis Basel, Switzerland 
[D-Cys(tBu)5]NPS Generous gift from N. Singewald, University of Innsbruck, Austria 
10x PCR Reaction Buffer (- MgCl2) Invitrogen, Grand Island, NY, USA 
25x Protease Inhibitor Cocktail Roche, Grenzach-Wyhlen, Germany 
4’,6-diamidino-2-phenylindole (DAPI) Carl Roth GmbH + Co., Karlsruhe, Germany 
Acrylamide Carl Roth GmbH + Co., Karlsruhe, Germany 
Agar-Agar, Kobe I Carl Roth GmbH + Co., Karlsruhe, Germany 
Ammonium persulfate (APS) RheinPerChemie GmbH, Hamburg, Germany 
Ampicillin  Carl Roth GmbH + Co., Karlsruhe, Germany 
Antibiotic-antimycotic solution Gibco, Darmstadt, Germany 
BamHI New England Biolabs, Ipswich, MA, USA 
Borate Merck KGaA, Darmstadt, Germany 
Bovine serum albumin (BSA): Albumin 
fraction V 
Carl Roth GmbH + Co., Karlsruhe, 
Germany 
Bromphenolblue Merck KGaA, Darmstadt, Germany 
Chloroform Carl Roth GmbH + Co., Karlsruhe, Germany 
Cy3-NPS Phoenix Pharmaceuticals, Karlsruhe, Germany 
Diethylpyrocarbonate (DEPC) Carl Roth GmbH + Co., Karlsruhe, Germany 
Dimethylsufoxide (DMSO) Invitrogen, Grand Island, NY, USA 
dNTPs Invitrogen, Grand Island, NY, USA 
Dulbecco’s modified Eagle’s medium 
(DMEM) Gibco, Darmstadt, Germany 
Ethanol Sigma-Aldrich, St Louis, MA, USA 
Ethidium bromide (EtBr) Sigma-Aldrich, St Louis, MA, USA 
Ethylene glycol Carl Roth GmbH + Co., Karlsruhe, Germany 
Ethylenediaminetetraacetic acid (EDTA) VWR, Darmstadt, Germany 
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ExGen 500 in vitro Transfection Reagent Fermentas, St Leon-Rot, Germany 
Fetal calf serum (FCS) Gibco, Darmstadt, Germany 
Fluorescein Invitrogen, Grand Island, NY, USA 
Forene 100 % (V/V) Abbott, Wiesbaden, Germany 
Formaldehyde min. 37 % Merck KGaA, Darmstadt, Germany 
Gelatin Carl Roth GmbH + Co., Karlsruhe, Germany 
Glucose Carl Roth GmbH + Co., Karlsruhe, Germany 
Glycerin ≥ 86 % Carl Roth GmbH + Co., Karlsruhe, Germany 
Glycin Carl Roth GmbH + Co., Karlsruhe, Germany 
Goat serum Sigma-Aldrich, St Louis, MA, USA 
Hank’s Balanced Salt Solution with 
phenol red Gibco, Darmstadt, Germany 
Isopropanol VWR, Darmstadt, Germany 
Kanamycin Carl Roth GmbH + Co., Karlsruhe, Germany 
Ketamine hydrochloride Essex Pharma GmbH, Munich, Germany 
LB Broth EZMix™ Powder Sigma-Aldrich, St Louis, MA, USA 
Metacam Boehringer Ingelheim, Biberach, Germany 
Methanol Carl Roth GmbH + Co., Karlsruhe, Germany 
Methylbutane Carl Roth GmbH + Co., Karlsruhe, Germany 
MgCl2 (50 mM) Invitrogen, Grand Island, NY, USA 
Milk powder Carl Roth GmbH + Co., Karlsruhe, Germany 
TFM Tissue Freezing Medium TBS Triangle Biomdeical Sciences, Inc, Durham, NC, USA 
NEBuffer 3 New England Biolabs, Ipswich, MA, USA 
NPS (rat) Bachem, Weil am Rhein, Germany 
PageRuler Prestained Protein Ladder Invitrogen, Grand Island, NY, USA 
peqGold Ladder-Mix (100-1000 bp) PeqLab, Erlangen, Germany 
peqGold Universal Agarose PeqLab, Erlangen, Germany 
Phosphate buffered saline (PBS) Gibco, Darmstadt, Germany 
Ponceau S AppliChem, Darmstadt, Germany 
Reaction Buffer for T4 ligase New England Biolabs, Ipswich, MA, USA 
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Rhodamine B Sigma-Aldrich, St Louis, MA, USA 
Rhodamine-NPS Phoenix Pharmaceuticals, Karlsruhe, Germany 
Shandon Immu-Mount Thermo Scientific, Waltham, MA, USA 
Sodium pyruvate Gibco, Darmstadt, Germany 
Sulfosalycilic acid Carl Roth GmbH + Co., Karlsruhe, Germany 
T4 ligase New England Biolabs, Ipswich, MA, USA 
Taq polymerase Invitrogen, Grand Island, NY, USA 
Tetraethylmethylenediamine (TEMED) Carl Roth GmbH + Co., Karlsruhe, Germany 
Trichloroacetic acid Carl Roth GmbH + Co., Karlsruhe, Germany 
Tris Carl Roth GmbH + Co., Karlsruhe, Germany 
Triton X-100 Carl Roth GmbH + Co., Karlsruhe, Germany 
Trypan blue Sigma-Aldrich, St Louis, MA, USA 
Trypsin Gibco, Darmstadt, Germany 
Tween 20 Carl Roth GmbH + Co., Karlsruhe, Germany 
XhoI New England Biolabs, Ipswich, MA, USA 
Xylazin hydrochloride Bayer Vital GmbH, Lederhosen, Germany 
β-mercaptoethanol Carl Roth GmbH + Co., Karlsruhe, Germany 
 
 
Supplementary Table 4. List of kits used in this work. 
 
 
 
Kit Firm 
BCA Protein Assay Reagent Thermo Scientific, Waltham, MA, USA 
Corticosterone (Rat/Mouse) ELISA DRG Instruments GmbH, Marburg, Germany 
NucleoSpin RNA II Kit Macherey-Nagel, Düren, Germany 
Omniscript Reverse Transcription Kit Qiagen, Hilden, Germany 
PureYield Plasmid Midiprep System Promega, Madison, WI, USA 
QIAquick Gel Extraction Kit Qiagen, Hilden, Germany 
QuantiFast SYBR Green PCR Kit Qiagen, Hilden, Germany 
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Supplementary Table 5. Buffer recipes used in this work. 
 
 
Buffer recipes 
 
Ampicillin 50 mg/ml 
-- 1 g in 20 ml H2O 
-- sterile filtration, aliquots of 1 ml at -20 °C 
 
Ammoniumpersulfate (APS) 10 % 
-- 1 g in 10 ml H2O, aliquots of 1 ml at -20 °C 
 
Agar plates for bacterial growth 
-- 20 g LB broth 
-- 15 g Agar-Agar (1.5 %) 
-- 1 l H2O 
-- add antibiotic (ampicillin at a final concentration of 100 µg/ml) 
-- cast plates 
 
DEPC H2O 
-- 2 ml DEPC in 2 l H2O, mix overnight at RT 
-- autoclave twice 
 
Freezing buffer for free-floating brain sections 
-- 25 % ethylene glycol 
-- 25 % glycerin 
-- 50 % PBS 
 
HRP substrate solution 
-- luminol stock 250 mM (266 mg in 6 ml DMSO) 
-- coumaric acid stock 90 mM (38 mg in 2.5 ml DMSO) 
 
LB medium 
-- 20 g LB broth in 1 l dH2O 
-- autoclave 
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Kanamycin 30 mg/ml 
-- 300 mg in 10 ml H2O 
-- concentration for agar plates: 30 µg/µl 
 
Ketamine-rompun 
-- 2% rompun 2% 
-- xylazin – xylazin hydrochloride 
-- 5% ketamine 10% (ketamine hydrochloride) 
-- in NaCl 
 
Laemmli dilution buffer (LAP+) for protein dilutions, 5x 
-- 5 % SDS 
-- 40 % glycin 
-- 160 mM Tris, pH = 6.8 
-- 5 % β-mercaptoethanol 
-- pinch of bromphenolblue 
-- H2O ad 10 ml 
-- aliquots of 0.5 ml at -20 °C 
 
Laemmli running buffer, 10x 
-- 25 mM Tris 
-- 192 mM glycin 
-- 0.5 % SDS 
-- H2O ad 1 l 
 
4 % PFA 
-- 100 ml Stock Solution A (27,6 g NaH2PO4 in 1000 ml ddH2O) + 400 ml Stock 
Solution B (35,6 g Na2HPO4 in 1000 ml ddH2O) 
-- 100 ml formaldehyde 37 % diluted with ddH2O up to 500 ml 
-- filter formaldehyde with two filters to remove calcium and prevent salt formation 
-- together: 1 l 4 % PFA in phosphate buffer 
 
Ponceau S solution 
-- 0.2 % Ponceau S 
-- 3 % trichloroacetic acid 
-- 3 % sulfosalycilic acid 
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-- dH2O ad 1 l 
 
TBS 10x 
-- 100 mM Tris 
-- 1.5 mM NaCl 
-- H2O ad 1 l, pH = 7.6 
-- for TBS-T: 1 l 10x TBS + 10 ml Tween-20, H2O ad 10 l, mix well 
 
Trypsin EDTA 
-- 1600 ml H2O 
-- 200 ml HBSS (10x with phenol red) 
-- 200 ml 10x trypsin 
-- mix and filter 
 
TBE 10x 
-- 90 mM Tris 
-- 90 mM borate 
-- 2.5 mM EDTA, pH = 8 
 
WetBlot Buffer 10x 
-- 250 mM Tris 
-- 1900 mM glycin 
-- H2O ad 1 l 
-- for 1x WetBlot Buffer ready-to-use: 100 ml 10x WetBlot Buffer + 700 ml H2O + 200 
ml methanol 
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Supplementary Table 6. List of software used in this work. 
 
 
 
Software Firm 
ImageJ software 
http://rsbweb.nih.gov/ij/, Rasband, W.S., 
ImageJ, U.S. National Institutes of Health 
Bethesda, Maryland, USA 
Adobe Photoshop CS5 Adobe 
LightCycler software 2.0 Roche Diagnostics, Mannheim, Germany
Confocal microscope: FluoView FV 1000 
2.1.2.5 
Olympus Soft Imaging Systems GmbH, 
Münster, Germany 
Statistical analysis: GraphPad Prism 
5.03 GraphPad Software, La Jolla, CA, USA 
ANY-maze 4.30 Stoelting, Wood Dale, IL, USA 
Epifluorescence microscope: cell^F 2.8 Olympus Soft Imaging Systems GmbH, Münster, Germany 
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